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 The aryl hydrocarbon receptor (AHR) is a ligand-activated signaling molecule 
which is involved in diverse biological functions ranging from cancer metastasis to 
immune regulation. This receptor forms a cytoplasmic complex with Hsp90, p23, and 
XAP2. We have previously reported that down-regulation of p23 triggers degradation of 
the AHR protein, uncovering a potentially dynamic event which controls the cellular 
AHR levels without ligand treatment. Here we investigate the underlying mechanisms for 
this p23 effect using wild-type HeLa and the p23 knockdown HeLa cells. Reduction of 
the Hsp90 and XAP2 contents, however, did not affect the AHR protein levels, implying 
that this p23 effect on AHR is more than just alteration of the cytoplasmic complex 
dynamics. Association of p23 with Hsp90 is not important for the modulation of the AHR 
levels since exogenous expression of p23 mutants with modest Hsp90-binding affinity 
effectively restored the AHR message and protein levels. The protein folding property of 
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p23 which resides at the terminal 50-amino acid region is not involved for this p23 effect. 
Results from our interaction study using the affinity purified thioredoxin fusion proteins 
and GST fusion proteins and isothermal titration calorimetry showed that p23 directly 
interacts with AHR and the interaction surface lies within AHR amino acid 1–216 and 
p23 amino acid 1–110. Down-regulation of the p23 protein content promotes the 
ubiquitination of AHR, indicating that p23 protects AHR from the ubiquitin-meditated 
protein degradation. However, the increased ubiquitination is not through the small 
ubiquitin-like modifier (SUMO) signaling pathway.  
Troubleshooting and optimization were paramount for understanding and 
evaluating the p23 and AHR interaction.  Specifically, the p23 mutant purification, p23: 
Hsp90 interaction, transient transfection, p23: AHR assay, and ITC study were phases of 
this research that required extensive time and critical thinking. These topics were further 
detailed to outline the specific problems encountered and the various steps taken to 
alleviate or optimize these issues.  
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Chapter 1: Introduction 
 
1.1. Aryl hydrocarbon receptor (AHR) 
The aryl hydrocarbon receptor is a xenobiotic transcription factor. In the early 
1960s, AHR was cited as a receptor for environmental carcinogen 2, 3, 7, 8- 
Tetrachlorodibenzo-p-dioxin (TCDD) [1]. Further ligand research has extended AHR 
responsiveness to include polycyclic aromatic hydrocarbons (PAHs)—3-
methylcholoanthrene, β-naphthoflavone, etc.— and halogenated aromatic hydrocarbons 
(HAHs) — polychlorinated and polybrominated dioxins, naphthalenes, benzenes, etc [2]. 
Exposure to these exogenous ligands induces toxicity as AHR signaling leads to the 
metabolism of the ligand. AHR is also responsive to various endogenous ligands 
including cAMP, 6-formylindolo[3, 2-b]carbazole (FICZ), and kynurenine (kyn) [3-6]. 
These ligands have been cited to maintain endogenous functions of AHR and T regulator 
cell differentiation.  
1.2. AHR signaling 
 In the absence of a ligand, AHR resides in the cytoplasm as part of a complex 
with three chaperone proteins—Hepatitis B virus X-associated protein 2 (XAP2), a 
homodimer of Heat shock protein 90 (Hsp90), and p23—important for AHR stability and 
ligand activation [7]. A ligand will enter the cell and bind to the ligand binding 
domain/PAS domain of AHR and trigger a conformational change which exposes the 
nuclear localization sequence (NLS) and shuttles the complex into the nucleus. Once in 
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the nucleus, AHR heterodimerizes with the aryl hydrocarbon receptor nuclear 
translocator (ARNT) and causes the stabilizing proteins to dissociate. The AHR: ARNT 
dimer binds to specific Xenobiotic/Dioxin response elements (X/DREs) of DNA and 
upregulates downstream gene expression [8]. There are three pathways of AHR signaling 
genes: the adaptive response pathways, the toxic response pathway, and the endogenous 
pathway [9]. The adaptive response pathway is primarily ligand-induced, DRE-driven 
xenobiotic-metabolizing enzymes, including phase I metabolism enzyme Cytochrome 
P450 (CYP) 1A1, 1A2, 1B1, and phase II metabolism enzymes like NQO1, UGT1A1, 
and ALDH3A1 [10, 11]. The toxic response pathway is an extension of the adaptive 
response pathway that has negative consequences for the exposed individual, for example 
TCDD and benzo[a]pyrene (B[a]P) exposure. TCDD exposure has been extensively 
researched and reported to affect multiple cellular process including but not limited to 
tumor promotion, cardiac dysfunction, immune suppression and embryotoxicity.   
Similarly, B[a]P metabolism induced by AHR activation is reported to be the start of lung 
tumorigenesis via DNA adduct formation with benzo[a]pyrene diol expoxide [12]. 
Endogenous pathways of AHR are centered around the immune system and response to 
endogenous ligands. The status of AHR activation regulates the balance of T cell 
differentiation from T helper 17 (Th17) to immunosuppressive T regulatory cells (Treg) 
[13]. For instance, TCDD induced activation favors Treg cells where as FICZ induced 
activation favors proinflammatory Th17 cells. In mouse models, an AHR deficiency in T 
cells suppresses collagen-induced arthritis [14]. AHR negatively regulates 
lipopolysaccharide (LPS) induced inflammatory responses in macrophages, and AHR 
suppresses dendritic cell immunogenicity via a kyn-dependent mechanism [15, 16].  
Recently AHR antagonist has been proposed to promote the expansion of human 
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hematopoietic stem cells, and the endogenous AHR agonist kyn produced by tryptophan-
2, 3-dioxygenase (TDO) promotes brain tumor progression, which implicates the 
potential role of AhR in stem cell and cancer biology [17]. 
1.3. Structure and domains of AHR 
 AHR is part of the basic helix-loop-helix (bHLH) Per-Arnt-Sim (PAS) 
superfamily [18]. This superfamily includes 19 other structurally similar mammalian 
proteins like the hypoxia inducible factor- 1 alpha (HIF-1α) [19]. AHR has three distinct 
domains that are vital for DNA, ligand, and co-activator interactions. The bHLH domain 
has a highly conserved sequence known for DNA-protein interaction. Within this 
domain, the nuclear localization sequence is located and masked by Hsp90 in the absence 
of a ligand. The PAS domain is comprised of two functional motifs PAS-A and PAS-B 
[20]. In conjunction with the bHLH domain, these motifs are essential for the strong 
ARNT dimerization and Hsp90 binding. The ligand binding domain (LBD) is also part of 
the PAS domain and initiates the conformational change to induce AHR signaling. Once 
the nuclear AHR/ARNT/DRE is formed, various co-activators—p300, SRC-1, p/CIP— 
are recruited to the transactivation domain (TAD) to control gene expression [20].  
 
Figure 1. Domain map of AHR 
24 
 
 
 
1.4. Stabilizing proteins of the AHR cytoplasmic complex 
1.4.1. Heat shock protein 90 (Hsp90). Hsp90 is part of a highly expressed heat 
shock protein family. Specifically for AHR signaling, Hsp90 is important for regulating 
AHR DNA binding activity. In the absence of Hsp90, AHR cannot form a stable protein 
complex but can intrinsically interact with DNA. Thus, Hsp90 is essential for repressing 
this intrinsic DNA binding activity of AHR. Hsp90 also binds directly to the PAS domain 
of AHR masking the LBD. Consequently, Hsp90 regulates ligand affinity and 
conformational change of AHR [21-23].  
1.4.2. Hepatitis B virus X-associated protein 2 (XAP2). Unlike Hsp90, XAP2 
does not interact directly with AHR but the c-terminus of Hsp90 dimer. XAP2 maintains 
the AHR cytoplasm and prevents premature nuclear localization in the absence of a 
ligand. Interestingly, it has been noted that CYP1B1 expression requires XAP2 but not 
other AHR-mediated P450 enzymes like CYP1A1 or CYP1A2 [24-26]. 
1.4.3. p23. Research centered on p23 primarily focuses on it as a co-chaperone 
protein of the Hsp90 dimer. Prior to this study, p23 has only been reported to interact 
with Hsp90 proteins of the AHR cytoplasmic complex and not directly with AHR. 
Additionally, p23 is vital for ligand-dependent nuclear translocation and protecting AHR 
from degradation [27-29].  
 In 2003, our lab determined that p23 is also important in the formation of 
AHR/ARNT/DRE complex [30]. Our lab noticed that enriched and purified AHR and 
ARNT loses their ability to gel shift in the presence of a ligand suggesting the need of 
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another protein to form the complex. When crude JM109 extract containing p23 
expression vector is included in the assay, we see a gel shift.  Similarly, in the absence of 
any other factor, i.e. AHR, ARNT, or a ligand, the gel shift complex is abolished. To 
further examine this, the same enriched proteins were combined in the presence of rabbit 
reticulate lysate. Rabbit reticulate lysate is known to contain many protein factors 
including p23. The rabbit lysate restored the complex. Similarly, purified p23 restored the 
AHR/ARNT/DRE complex in a ligand-dependent manner. Interestingly, the restoration 
was not caused by a general protein effect since BSA, casein, nor non-fat dry milk could 
restore the gel shift [30].  
In 2012, we deduced that p23 protects AHR protein from degradation [31]. This 
was observed by knocking down p23 via a lentiviral infection in mouse hepatoma cells 
(Hepa1c1c7). Western analysis showed the protein level of p23 and AHR compared to 
the WT and negative control underwent significant degradation of AHR. Upon the 
transfection of exogenous p23 to the knockdown cell line, the AHR protein levels are 
restored [31]. This introduces an interesting phenomenon that altered p23 protein levels 
result in AHR protein degradation. 
1.5. Regulation of AHR  
 After initiating the transcription of the designated downstream genes, the AHR: 
ARNT complex dissociates from DNA and ARNT exposing the nuclear export sequence 
(NES). AHR is ubiquinated in the nucleus and degraded or AHR is exported from 
nucleus via chromosome region maintenance protein 1 (CRM-1) export receptor. AHR is 
ubiquinated in cytoplasm and targeted to 26S proteasome for degradation. Note that this 
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pathway is linear and the degradation of the AHR is a terminal step regardless of whether 
it occurs within the nucleus or cytoplasm [32].  
 Conversely, AHR activity can be regulated by the aryl hydrocarbon receptor 
repressor (AHRR). AHRR expression is induced upon AHR agonist exposure in both cell 
lines and mouse tissues [33], and negatively regulates AHR signaling by competing via 
heterodimerization with ARNT to prevent AHR: ARNT complex formation.  AHRR: 
ARNT complex is regulated by small ubiquitin-like modifier (SUMO), which binds to 
the C-terminal three evolutionarily conserved SUMOylation consensus sequences within 
AHRR [34].  AHRR expression level was found lowered in both cancer cell lines and 
primary tumors because of aberrant methylation at the DRE promoter sites, which leads 
to imbalance of cell cycle progression control and subsequently promotes tumorigenesis 
[35]. 
Recently, SUMO has also been sited to directly bind to AHR in MCF-7 cells [36]. 
This SUMOylation stabilizes AHR via ubiquitin inhibition. DeSUMOylation is induced 
by SENPs. SENPs cleave the isopeptide bond between SUMO and the lysine residue of 
the protein to which it is attached. Three SENPs have been found in the cell nucleus, 
SENP1, 2, and 3 [36].   
1.6. AHR in cancer  
The AHR is hyper-expressed in a variety of human and rodent tumors including 
breast, lung, gastric, brain, ovarian, pancreatic, and oral carcinomas, Hodgkin's 
lymphoma, chronic lymphocytic leukemia, and adult T-cell leukemia [37]. In addition to 
being hyper-expressed, the AHR also appears to be constitutively active in a diverse array 
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of human cancers including glioblastomas, adult T cell leukemias, breast, oral, lung, 
liver, and prostate adenocarcinomas [37]. This constitutively active response reflects the 
presence of endogenous ligands since no functional AHR mutation were identified [38]. 
An early indication of the presence of endogenous AHR ligands in malignant cells came 
from studies demonstrating that CYP1A1 inhibition increases and ectopic CYP1A1 
expression decreases baseline AHR activity, a result attributed to the ability of CYP1A1 
to metabolize an undefined endogenous ligand(s) [38]. Of these endogenous ligands, 
tryptophan metabolites generated in the kynurenine pathway of tryptophan catabolism 
seem to be the most relevant in the cancer setting [39]. 
The classical understanding of AHR's role in cancer is focused on the production 
of mutagenic intermediates, DNA damage, and subsequent generation of mutations [39]. 
The downstream genes of AHR activation often leads to highly reactive epoxides as the 
downstream genes of AHR, CYP1A1, -1A2, -1B1 metabolize the PAH ligands. These 
intermediates are biomarkers of chemical-induced genotoxicity. However, AHR also 
influences later steps in cancer progression. Additional studies assessing functional 
outcomes demonstrated that: 1) transfection of non-invasive breast epithelial cells with an 
AHR expression plasmid conveys the ability of cells to invade in 3D cultures, 2) AHR 
inhibition or knockdown in malignant cell lines reduces tumor cell migration, invasion 
and formation of 3D mammospheres, and 3) AHR inhibition attenuates apoptosis 
resistance to chemotherapeutics and UV light in multiple cancer cell types [37].  
Looking into the molecular mechanism through which AHR influences tumor 
invasion and metastasis, T-cadherin, E-cadherin, and Slug—proteins linked to tumor 
invasion—gene transcription has been sited to be upregulated due to AHR activity [39]. 
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Similarly, AHR has been linked to cytokine regulation associated with tumor 
inflammation, migration and angiogenesis [37]. Environmental and endogenous AHR 
ligands also promote expression of matrix metalloproteinases, c-Myc, epiregulin, and 
activation of the ERK signaling pathway, all of which contribute to tumor invasion and 
metastasis [37]. In addition to the invasiveness and metastatic characteristics AHR 
activity has been linked, AHR has been identified in cancer stem cells (CSCs) and 
significant down regulation resulted in less CSCs and chemoresistance via ABCG2 
regulation [37].  
It is worthwhile to note that overexpression or constitutive activity of AHR is 
multi-faceted and can be a negative or positive prognostic factor. For instance, 
constitutively active AHR overexpression in MCF-7 breast cancer cells and Jurkat T cells 
inhibited growth in both cell lines and induced apoptosis in Jurkat cells [38]. AHR’s 
involvement in various signaling pathways is critical to tumor homeostasis. As 
knowledge regarding the regulation of AHR expands, so does the potential to target AHR 
as a novel anticancer agent. Yet, there is still much debate whether utilizing AHR agonist 
or antagonist are the avenue to pursue due to complex signaling nature [38].   
1.7. AHR in other disease states 
1.7.1. AHR in autoimmune diseases. Previous studies have demonstrated that 
activation of AHR by specific ligands regulates the generation of regulatory T cells, 
modulates the Th1 and Th2 balance [40], and increases the proportion of Th17 cells and 
their production of cytokines to promote the development of autoimmune diseases [41].  
But notably, the immunomodulation effect of AHR might depend upon the 
interaction among AHR signaling pathway and other transcription factor signaling 
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pathways involved in the differentiation or cytokines production of CD4 T helper cells 
subsets, and also such immunomodulation effects might occur in a ligand-specific fashion 
[42]. The importance of the AHR signaling pathway in the process of both immune 
system development and immune modulation has been increasingly investigated since 
Funatake et al. first described the importance of AHR signaling in the generation of Tregs 
in vivo [43]. Since then, AHR has been linked to immune modulation in 5 unique ways: 
1. Direct regulation of target gene expression  
2. Indirect interaction with other types of immune cells  
3. Endocrine system specific sex hormone signaling pathway  
4. Epigenetic modulation of target genes  
5. Ubiquitin ligase activity modulation 
Aberrant CD4 T cells or imbalance of CD4 T cell subsets contribute to the genesis and 
prognosis of inflammatory autoimmune diseases. Crohn’s disease, also known as Crohn 
syndrome and regional enteritis, is a type of inflammatory bowel disease (IBD) that may 
affect any part of the gastrointestinal tract from mouth to anus, causing a wide variety of 
symptoms, which results from a combination of genetic and environmental factors that 
trigger an inappropriate immune response to commensal gut bacteria [44]. Since Crohn’s 
disease affects millions of people worldwide, it is essential to investigate the underlying 
mechanisms of pathogenesis so that new and more effective therapeutics can be 
developed. Additionally, activation of AHR may modulate immune and inflammatory 
responses, so studying the effects of AHR activation on the pathogenesis of Crohn’s 
disease is warranted [45].  
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A recent study showed that pretreatment with TCDD suppressed inflammation in 
the gut of the 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced murine model of colitis. 
These results also demonstrated that TCDD activated AHR decreased pro-inflammatory 
cytokines levels of interleukin 6, IL-12, interferon-gamma, and tumor necrosis factor-
alpha and induced the differentiation of Foxp3 Treg cell. Together this decreased colonic 
inflammation in a murine model of colitis in part by generating regulatory immune cells 
[46]. 
The pathogenesis of IBD is believed to involve an altered balance between 
effector and regulatory T cells. Intestine tissue from patients with IBD expressed 
significantly less AHR than controls [47], Experimental animal models of colitis show 
that attenuation of AHR receptor expression resulted in a protective effect during DSS-
induced colitis, while the absence of AHR exacerbated the disease. Abnormal AHR 
pathway activation in the intestinal mucosa of IBD patients may promote chronic 
inflammation [47]. 
Several reports suggest that the prevalence of systemic lupus erythematosus 
(SLE), is also increasing in recent years. Environmental factors likely play a major role in 
such high morbidity [48]. Traditionally, SLE is identified as a Th2-type autoimmune 
disease, however, both Th17 and Treg cells are involved in the pathogenesis of SLE as 
the dynamic balance between these cells is damaged in SLE patients. Restoring the 
immune balance among Th1, Th17 and Treg cells, rather than exclusively focusing on 
Th17 cells, will yield better results for the treatment of SLE [49]. Furthermore, there is 
evidence that Th17 and Treg cells arise in a reciprocal manner, depending on potentially 
pro- or anti-inflammatory cytokines (IL-6, TGF-β, IL-23) and activation of specific 
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transcription factors including AHR [41, 49]. By the aid of the New Zealand Black/New 
Zealand White F1 hybrid (B/W) mouse model of SLE, one study showed that TCDD 
chronic exposure significantly lowered thymic and splenic weights, decreased the 
percentage of CD4 T cells, and also demonstrated an immunosuppressive effect on the 
prognosis of SLE.  
Allergic asthma and lung inflammation is another kind of inflammatory 
autoimmune disease of the respiratory system. Millions of individuals worldwide are 
afflicted with acute and chronic respiratory diseases, which often occur as a result of 
altered immune responses, causing temporary and permanent disabilities and even death 
[50]. Asthma is characterized by the infiltration of the airways with various types of 
immune cells including eosinophils, mast cells, and T lymphocytes, leading to airway 
obstruction and airway remodeling, however, it is mainly caused by Th2 lymphocytes 
secreting IL-4 and IL-5 [51]. AHR specific agonists TCDD, Curcumin and FICZ have 
been shown to suppress allergic immune responses in several mice models, providing 
evidence for the involvement of AHR ligands in the pathogenesis of allergic asthma. An 
in vitro study found that treatment with FICZ decreased Th2 cell differentiation via the 
inhibition of expression of Th2 transcription factors, GATA3 and STAT6. An in vivo 
study of the ovalbumin-induced allergic asthma mouse model also found that FICZ 
treatment alleviated the pathogenesis of asthma and significantly reduced pulmonary 
eosinophilia, differentiation of Th2 cells and production of cytokines [52]. Curcumin 
inhibited recruitment of eosinophils into the lung airways, airway hyper responsiveness, 
and expression of IL-4, in OVA-sensitized mice. OVA challenge resulted in activation of 
the production of inducible nitric oxide (iNOS) in lung tissue, inflammatory cytokines, 
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recruitment of eosinophils to lung airways, and airway hyper-responsiveness to inhaled 
meth-choline, while pretreatment of mice with curcumin inhibited the OVA-induced 
inflammation. An in vitro study of a human airway epithelial cell line, A549, showed that 
curcumin decreased iNOS and nitric oxide (NO) production induced by IFN- γ. Together, 
the results suggested that the AHR ligand curcumin contributed to anti-inflammatory 
activity in the murine asthma model and lung epithelial cell A549 through suppression of 
NO [53]. 
Rheumatoid arthritis (RA) is the most common type of inflammatory and 
autoimmune arthritis, and is characterized by chronic inflammation of the synovium and 
subsequent joint destruction, while the pathogenic mechanisms of RA remain largely 
unknown. However, recent studies have demonstrated that many T cell subsets, including 
IL-17-producing Th17 and Treg cells, play important roles in pathogenesis of RA [54]. 
On one hand, Th17 cells induced by TGF-β plus IL-6 or IL-21, secrete IL-17 isoforms 
that in association with other cytokines, such as IL-1 or TNF-α, synergistically activate 
synovial fibroblasts to produce matrix metalloproteinases. On the other hand, Treg cells, 
induced by TGF-β signaling, exert suppressive functions that are important for 
immunologic tolerance. The Th17/Treg cell balance is a new paradigm for autoimmunity 
[55]. A previous study indicated that the development of experimental autoimmune 
arthritis depends on the presence of AHR in T cells [55]. AHR deficiency blocks 
cartilage destruction and reduces matrix metalloproteinase-3 levels and ameliorated 
collagen II-induced arthritis (CIA), a mouse model of RA, while demonstrating that the 
pro-inflammatory effects of AHR in mice with collagen-induced arthritis can be mediated 
by Th17 cells and IL-22. Another study showed that TCDD-activated AHR signaling 
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contributed to up-regulation of the expression of IL-1 beta, IL-6 and IL-8, that was 
transmitted via the NF-kappa β and ERK signaling cascades [56]. The study also found 
that AHR expression could be enhanced by the cytokine TNF-α, and cigarette smoking 
and exposure to TCDD contributed to promote RA inflammatory processes [56]. 
Resveratrol inhibits the transactivation of several dioxin-inducible genes including 
CYP1A1 and interleukin-1 beta, both in vitro and in vivo [57]. Another research group 
found that resveratrol prevents the production of pro-inflammatory cytokines such as IL-
6, TNF-α, IL-17, and IFN-γ in CIA mice, and also inhibits Th17 cell differentiation and 
autoantibody production by B cells, thus suppressing disease development [58]. 
Strong auto-reactive Th17 activity and weak Tregs activity contribute 
significantly to development of multiple sclerosis (MS), an autoimmune inflammatory 
disease of the CNS that afflicts at least 400,000 people in the United States and 1.4 
million people worldwide [59]. Experimental autoimmune encephalomyelitis (EAE), the 
best-characterized murine model of MS, resembles MS in many aspects. Rouse et al. 
investigated the therapeutic efficacy of two AHR agonists, indole-3-carbinol (I3C) and 
diindolylmethane (DIM) against EAE. Their results demonstrated that pretreatment of 
EAE mice with I3C or DIM completely prevented clinical symptoms and cellular 
infiltration into the CNS. Also, post-treatment of EAE with I3C or DIM proved highly 
effective in curtailing the overall severity of the disease. The molecular mechanism 
involves AHR regulation of Foxp3 induction and suppression of Th17 cells [59]. 
Many AHR-mediated immune regulatory mechanisms have been discovered, 
which will likely not only enhance our understanding of the molecular pathogenesis of 
autoimmune inflammation diseases, but also contribute to research and development of 
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new potential drug candidates that target AHR or downstream elements of its signaling 
pathway for the therapy of inflammatory autoimmune diseases. To develop such 
therapies, we need to establish a firm understanding of the mechanisms of action that 
might be involved during the course of AHR-mediated immune regulation.  
1.7.2. AHR in cardiovascular diseases. Numerous experimental and 
epidemiological studies have demonstrated that PAHs, which are major constituents of 
cigarette tobacco tar, are strongly involved in the pathogenesis of the cardiovascular 
diseases (CVDs). Knowing that PAH-induced toxicities are mediated by the activation of 
AHR, which regulates the expression of a group of xenobiotic metabolizing enzymes 
(XMEs) such as CYP1A1, CYP1A2, CYP1B1, NQO1, and GSTA1, suggests a direct 
link between AHR-regulated XMEs and CVDs [60]. Therefore, identifying the 
localization and expression of the AHR and its regulated XMEs in the cardiovascular 
system (CVS) is of major importance in understanding their physiological and 
pathological roles.  
Generally, it was believed that the levels of AHR-regulated XMEs are lower in 
the CVS than in the liver; however, it has been shown that similar or even higher levels 
of expression are demonstrated in the CVS in a tissue- and species-specific manner [60]. 
Moreover, most, if not all, AHR-regulated XMEs are differentially expressed in most of 
the CVS, particularly in the endothelium cells, aorta, coronary arteries, and ventricles 
[60]. Although the exact mechanisms of PAH-mediated cardiotoxicity are not fully 
understood, several mechanisms are proposed. Generally, induction of CYP1A1, 
CYP1A2, and CYP1B1 is considered cardiotoxic through generating reactive oxygen 
species (ROS), DNA adducts, and endogenous arachidonic acid metabolites [60]. 
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However, the cardioprotective properties of NQO1 and GSTA1 are mainly attributed to 
the antioxidant effect by decreasing ROS and increasing the levels of endogenous 
antioxidants [60]. Therefore, imbalance of the expression of cardioprotective and 
cardiotoxic XMEs is the main determinant of PAH-mediated cardiotoxicity. 
1.7.3. AHR in diabetes. Hyperglycemia is an independent risk-factor for 
development of diabetic vascular complications. The molecular mechanisms that are 
activated by glucose in vascular cells and could explain the development of vascular 
complications are still poorly understood. A putative binding site for AHR was identified 
in the glucose-responsive fragment of the promoter of thrombospondin-1 (TSP-1), a 
potent anti-angiogenic and pro-atherogenic protein involved in development of diabetic 
vascular complications [61]. AHR was expressed in aortic endothelial cells (EC), 
activated and bound to the promoter in response to high glucose stimulation of EC [61]. 
The constitutively active form of AHR induced activation of the TSP-1 gene promoter. In 
response to high glucose stimulation, AHR was found in complex with Egr-1 and AP-2, 
two other nuclear transcription factors activated by glucose in EC that have not been 
previously detected in complex with AHR [61]. The activity of the DNA-binding 
complex was regulated by glucose through the activation of hexosamine pathway and 
intracellular glycosylation [61]. This links the activation of AHR to the pathological 
effects of hyperglycemia in the vasculature. 
The epidemic of obesity and diabetes is widely recognized as an emerging public 
health problem of enormous magnitude. Numerous man-made pollutants activate AHR 
and are risk factors for type 2 diabetes. In 2011, Wang et al. discovered KO mice 
displayed enhanced insulin sensitivity and improved glucose tolerance, accompanied by 
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decreased PPAR-α and key gluconeogenic and fatty acid oxidation enzymes. AHR 
agonists increased PPAR-α expression in c7 cells [62]. Both AhR and Bmal1 siRNA 
reduced PPAR-α and metabolism genes [62]. Moreover, rhythms of BMAL1 and blood 
glucose were altered in KO mice [62]. This indicates a link between AHR signaling, 
circadian rhythms, and glucose metabolism. Furthermore, hepatic activation of the 
PPAR-α pathway provides a mechanism underlying AHR-mediated insulin resistance 
[62]. Understanding the mechanisms involved in AHR-induced diabetes has the potential 
to revolutionize our understanding of type 2 diabetes. 
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Chapter 2: p23 protects the human aryl hydrocarbon receptor from degradation via 
a heat shock protein 90-independent mechanism 
 
2.1. Introduction 
 The aryl hydrocarbon receptor (AHR) is best known as a ligand-activated 
transcription factor: upon ligand binding, the AHR protein complex, which consists of 
AHR, Hsp90, XAP2, and p23 in the cytoplasm, translocates into the nucleus and then 
dissociated upon formation of the AHR/ARNT heterodimer. This heterodimer is 
responsible for recruitment of coactivators locally to remodel chromatin structure, 
allowing transcription of its target genes, notably the xenobiotic metabolizing enzymes 
[63, 64]. In addition to regulation of drug metabolism, AHR is involved in diverse 
cellular events – organ development [65, 66], glucose homeostasis [67], immune 
responses [68] stem cell differentiation [69], and cancer cell invasion and metastasis [70]. 
Although endogenous ligands of AHR have been identified, which are FICZ, kynurenine, 
and other tryptophan metabolites [71, 72], the precise mechanism to explain many AHR 
functions may very well go beyond its well established cell signaling mechanism and are 
largely unknown. Some of its action is peculiar and complex: different ligands of AHR 
can cause completely opposite immune responses [68] and AHR may promote or 
suppress cancer cell invasion and metastasis, depending on the cell types [73-75]. 
 In addition to being part of the AHR cytoplasmic complex, p23 is present as a co-
chaperone in a number of Hsp90 client complexes – namely progesterone receptor [76], 
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estrogen receptor [77], androgen receptor [78], and telomerase [79]. Interference of the 
Hsp90 and p23 interaction has been reported to be a viable strategy to suppress cancer 
cell growth and metastasis [81, 82]. And it appears that most, if not all, of the p23 
function involves Hsp90.   
 Many aggressive tumors appear to overexpress AHR [72, 83] whereas increased 
AHR levels in lung tumor, on the other hand, suppresses epidermal to mesenchymal 
transition [70]. It would be beneficial to understand how the AHR protein levels can be 
maintained from a perspective of homing in AHR as a potential drug target. However, we 
currently have very limited knowledge with regards to mechanisms which regulate the 
cellular AHR levels. The best known mechanisms that trigger the AHR proteasomal 
degradation are mediated through binding of a ligand [83] and treatment with an Hsp90 
inhibitor such as geldanamycin [84]. In addition, we have reported that down-regulation 
of p23 causes degradation of the AHR protein in various mouse and human cell lines 
[31]. Here we present data supporting that this p23 effect is not merely changing the 
dynamics of the AHR cytoplasmic complex. This p23-mediated AHR protein degradation 
is not Hsp90-dependent and appears to be mediated through ubiquitination.  
2.2. Materials and methods 
 2.2.1. Reagents. 3-MC and cell culture media were purchased from Sigma (St. 
Louis, MO). MG132 was purchased from Cayman Chemical (Ann Arbor, MI). Cell 
culture reagents, if not specified, were purchased from Invitrogen (Carlsbad, CA). All 
other chemicals, if not specified, were purchased from Sigma (St. Louis, MO) or Fisher 
Scientific (Pittsburgh, PA). Oligonucleotides were purchased from Invitrogen (Carlsbad, 
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CA). The DRE oligonucleotides conjugated with IRDye 680 (OL439, IRD680-
TCGAGTAGATCACGCAATGGGCCCAGC; OL440, IRD680-
TCGAGCTGGGCCCATTGCGTGATCTAC) were purchased from Integrated DNA 
Technologies (San Diego, CA). Fetal bovine serum was purchased from Tissue Culture 
Biologicals (Tulare, CA) or Thermo Fisher Scientific (Rockford, IL). HeLa (ATCC, 
Manassas, Virginia) and the stable cells derived in our laboratory were grown in DMEM 
supplemented with 10% fetal bovine serum, 2 mM GlutaMAX-I, 10 U/ml of penicillin, 
and 10 mg/ml of streptomycin. All cells were maintained at 37℃ and 5% CO2. 
Endofectin transfection reagent was purchased from GeneCopeia (Rockville, MD). 
EcoTransfect reagent was purchased from Oz Biosciences (San Diego, CA). Anti-AHR 
rabbit IgG (SA210) was purchased from Enzo Life Sciences (Farmingdale, NY). Anti-
p23 mouse IgG (JJ3) was purchased from Thermo Fisher Scientific (Rockford, IL). Anti-
GAPDH rabbit IgG (G9545) and anti-thioredoxin rabbit IgG (T0803) were purchased 
from Sigma (St. Louis, MO). Anti-GFP rabbit IgG (sc-8334), anti-Hsp90 goat IgG (N-
17), and anti-ubiquitin P4D1 mouse IgG (sc-8017) were purchased from Santa Cruz 
Biotechnology (Dallas, TX). Anti-β-actin mouse IgG was purchased from Ambion 
(Austin, TX). Anti-XAP2 (ARA9) rabbit IgG was purchased from Novus Biologicals 
(Littleton, CO). Anti-SUMO1 (Y3111) mouse IgG was purchased from UBPBio (Aurora, 
CO). All secondary IgGs conjugated with IRDye 800CW or 680 were purchased from LI-
COR Bioscience (Lincoln, NE). The Hsp90AA1 (Hsp90 alpha)-specific 
(NM_001017963) and XAP2 (AIP)-specific (NM_001302959.1) shRNA pLKO.1 
plasmids were purchased from Dharmacon (Lafayette, CO). The psPAX, pMD2.g, and 
pLKO.1 shRNA scramble plasmids for lentivirus generation and the pET-His6 plasmid 
for Hsp90 expression were purchased from Addgene (Cambridge, MA). The codon 
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humanized pGFP2-N2 plasmid was purchased from BioSignal Packard (Montreal, 
Canada). The pET-42a plasmid was purchased from MilliporeSigma (Burlington, MA). 
The pThioHis plasmid was purchased from Invitrogen (Carlsbad, CA). The full-length 
human Hsp90 cDNA was purchased from Sino Biological (Beijing, China). Cobalt 
agarose beads and IPTG were purchased from Gold Biotechnology (St. Louis, MO). 
Gibson assembly kit was purchased from New England BioLabs (Ipswich, MA). 
QuikChange Lightning site-directed mutagenesis kit was purchased from Agilent (San 
Diego, CA). Millipore Amicon Ultra-4 device was purchased from Thermo Fisher 
Scientific (Grand Island, NY). Nitrocellulose membrane for LI-COR western and 10X 
orange loading dye for gel shift assay were purchased from LI-COR Bioscience (Lincoln, 
NE). Bovine serum albumin and cycloheximide were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). Glutathione magnetic beads and Protein G Dynabeads 
were purchased from Thermo Fisher Scientific (Rockford, IL). Guanidine hydrochloride 
was purchased from Amresco (Solon, OH).   
2.2.2. Generation of Hsp90 and XAP2 stable knockdown cells. Protocols for 
generation of shRNA-containing lentiviruses and lentiviral infection were previously 
described [31]. Hsp90 knockdown HeLa cells were generated using the Hsp90 alpha-
specific shRNA (#1, 3299; #2, 3300; #3, 3301; #5, 2153; #6, 8563) whereas XAP2 
knockdown HeLa cells were generated using the XAP2-specific shRNA #2 (3923) or #3 
(3924). These cell lines were generated by previous lab mates.  
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2.2.3. Cloning of recombinant plasmids. The GST fusion of p23 with the GST 
tag at the N-terminus was generated by cloning the full-length human p23 cDNA into the 
Nco I/PST I sites of the pET-42a plasmid. The GST fusion plasmids carrying a p23 
mutant cDNA were generated by using the sense and antisense sequences (Fig. 2) to 
perform QuikChange site-directed mutagenesis. 
  
Figure 2. Primer design for GST-p23 mutants. Wild-type human p23 coding sequence 
from nucleotide 301 to 360 is shown, with translation start site at +1. Amino acid (aa) 
106 to 112 represents the Wild-type human p23 coding sequence from nucleotide 301–
360 is shown, with translation start site as +1. Amino acid (aa) 106–112 represents the 
region where point mutants W106A, W109A, D108A, D111A, and D112A were 
generated. Sense mutagenic primers are shown with the mutated codons bolded and the 
nucleotide numbers. Lines represents the length of the primers. The antisense mutagenic 
primers are the reverse complement of the sense primers. 
 
The GFP fusion plasmids carrying a p23 cDNA were generated by cloning the 
corresponding cDNA with a Kozak sequence (ACCATGGGT) into the Eco RV site of 
the pGFP2-N2 plasmid using Gibson assembly to generate GFP at the C-terminus of the 
fusion protein. The pThioHis plasmid was used to generate the thioredoxin (TH) fusions 
of an AHR construct. The TH553 expressing plasmid carrying the aa1-295 human AHR 
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cDNA was generated previously [85]. The TH217-549 (aa217-549) and TH515 (aa516-
849) expressing plasmids were generated by cloning the corresponding cDNA into the 
Stu I site of the pThioHisA plasmid using Gibson assembly. Similarly, 6His- AHR aa1-
216 was generated by cloning the corresponding cDNA into Ssp I site of the pET-His 6 
TEV plasmid. The full-length human Hsp90 cDNA was amplified and cloned into the 
Ssp I site of the pET-His6 plasmid using Gibson assembly. All oligonucleotides used for 
recombinant protein expression is in Table 1. All cloned plasmids were sequenced to 
confirm the identity (Functional Biosciences, Madison, WI). DNA was purified for 
transfection using Zymopure maxiprep kit (Zymo Research, Irvine, CA) and stored at -
20℃. 
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Table 1: Summary of all oligonucleotides used during this study. 
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2.2.4. Bacterial expression of GST fusions of p23, thioredoxin fusions of 
AHR, and histidine fusion of Hsp90. Metal-affinity purification was performed as 
previously described [86]. In brief, 600 ml of culture was induced with 1 mM IPTG for 5-
6 h at 37℃. Metal-affinity purification using cobalt resin was performed and the affinity 
purified fractions were eluted with 0.5 M imidazole. All fractions were concentrated, 
when necessary, using the Amicon Ultra-4 device and then stored at -80℃. 
2.2.5. Western analysis. Protocols for LI-COR Western analysis was previously 
described [86]. The transferred nitrocellulose membrane was blocked in 5% BSA for 30 
min, followed by the primary antibody incubation in the same blocking buffer overnight. 
Dilutions for antibodies were as follows: 1:1,000 for p23 (JJ3), 1: 5,000 for AHR 
(SA210), 1: 5,000 for β-actin and GAPDH, 1:200 for Hsp90 (N-17), 1:5,000 for XAP2, 
1:5,000 for thioredoxin (T0803), 1:1,000 for ubiquitin (P4D1), 1:1,000 for SUMO1 
(Y3111).   
2.2.6. GST-pulldown assay.  For the Hsp90: p23 interaction study, a normalized 
amount (4 µg) of GST, GST-p23, or GST-p23 mutants was incubated with 5 µL of the 
affinity purified Hsp90 (20 µg) in 1 mL of the assay buffer (25 mM HEPES, pH 7.4, 100 
mM KCl, 10% glycerol, 5 mM ATP, 0.01% NP-40, 20 mM sodium molybdate) at 30℃ 
for 20 min. The sample solution was then incubated with 20 µL of the pre-equilibrated 
glutathione magnetic beads at 4℃ for 2 h while mixing at a rotation of 42 rpm. The pellet 
was washed four times with the wash buffer (assay buffer plus 0.4% Tween-20) and then 
eluted with 30 µL of the SDS–PAGE sample buffer. The samples were subjected to 12% 
SDS–PAGE, followed by LI-COR Western analysis using the anti-GST or anti-Hsp90 
IgG for signal detection. 
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 For the p23: AHR interaction study, a normalized amount (100 µg) of a 
thioredoxin fusion of an AHR construct (TH553, TH217-549 or TH515) was incubated 
with 3 µL of GST-p23 (7.5 µg) or GST (3.5 µg) in 200 µL of the assay buffer (25 mM 
HEPES, pH 7.4, 100 mM KCl, 10% glycerol, 1 mg/ml of BSA, 0.01% NP-40, 10 mM 
DTT) at room temperature for 30 min. BSA was included in the assay buffer to minimize 
non-specific protein interactions. The sample solution was then incubated with 3 µL of 
the pre-equilibrated glutathione magnetic beads at 4℃ overnight at a rotation of 42 rpm. 
The pellet was washed four times with the wash buffer (assay buffer plus 0.2% Tween-
20) and then eluted with 20 µL of the SDS–PAGE sample buffer. The samples were 
subjected to 15% SDS–PAGE, followed by Western analysis with a LI-COR CLX 
Odyssey system (Lincoln, NE) analysis using the anti-thioredoxin IgG for signal 
detection.  
2.2.7. Electrophoretic mobility shift assay. Samples containing AHR and 
ARNT (2 µL/1 µL (4 µg/ 1 µg) of affinity purified Pichia AHR/ARNT or 0.01 µL/1 µL 
(7 µg/ 1 µg) of TH553/affinity purified Pichia ARNT) were incubated with 5 mg of 
Pichia ySMD1163 extract in the presence or absence of a ligand (10 µM βNF or DMSO) 
at 30℃ for 10 min. The final volume was adjusted to 11 µL with the HEDG buffer (25 
mM HEPES, 10 mM EDTA, 1 mM DTT, 10% glycerol). 
In some cases, Pichia extract was replaced by p23 (1 µL of affinity purified GST-
p23 (40 µg) or 6His-p23 (40 µg)). Calf thymus DNA (0.3 µg) and poly-dIdC (1.5 µg) 
were then added for another incubation for 10 min at room temperature. After that, 
samples were incubated with the IRDye 680 conjugated DRE (0.5 pmol) for 10 min at 
room temperature. 10X orange loading dye was then added to each sample, followed by 
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electrophoresis on a native 5% polyacrylamide TBE gel and resolved at 185 volts for 2 h 
at 4℃. The sandwiched gel was analyzed directly using a LI-COR CLx Odyssey near-
infrared imaging system (Lincoln, NE).  
2.2.8. Transient transfection for whole cell extract generation 
 When the p23KD HeLa cells were about 90% confluence in a 6-well plate, 
transient transfection was initiated using the Endofectin reagent as follows: plasmid (4 
μg, pGFP2-N2 empty plasmid or cloned pGFP2-N2 plasmid carrying the p23 or p23 
mutant cDNA) and Endofectin reagent (8 μL) were incubated in a final volume of 200 μL 
of complete media for 20 min before being added onto a well containing 2 mL of fresh 
media. Media was exchanged after 24 h and cells were harvested 72 h after transfection. 
The lysis buffer (25 mM HEPES, pH 7.4, 0.4 M KCl, 1 mM EDTA, 1 mM DTT, 10% 
glycerol, 1 mM PMSF, and 2 µg/ml of leupeptin) was used to harvest cells from a 75 cm2 
flask (300 µL) or wells from a 6-well plate (50 µL/well). After three cycles of 
freeze/thaw, lysates were kept on ice for 30 min and then centrifuged at 14,000 g for 10 
min at 4℃. The supernatants were defined as whole cell extract and were subjected to LI-
COR Western analysis.  
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2.2.9. Ubiquitinated and SUMO1 protein analysis. Wild-type HeLa and the 
p23KD HeLa cells were grown to 90% confluence in 100 mm culture dishes. HeLa cells 
were treated with DMSO, 10 µM MG132, or co-treated with 1 µM 3-MC and 10 µM 
MG132 for 2 h. The p23KD HeLa cells were treated with DMSO or 10 µM MG132 for 2 
h. Cells were harvested and lysates were prepared using the lysis buffer (25 mM HEPES, 
pH 7.4, 0.15 M KCl, 1 mM EDTA, 1 mM DTT, 10% glycerol, 1 mM PMSF, 2 µg/ml of 
leupeptin, and 10mM N-ethylmaleimide). Samples (2 mg, from four 100 mm dishes) 
were subjected to immunoprecipitation with the anti-AHR SA210 IgG (2 µL) for 30 min 
at room temperature. The pre-equilibrated Protein G Dynabeads (3 µL) were added to 
each sample with the assay buffer (25 mM HEPES, pH 7.4, 0.15 M NaCl, 1 mM EDTA, 
1 mM DTT, 10% glycerol, 0.1% Tween-20, and 1 mg/mL of BSA) and the samples were 
incubated with a rotation of 45 rpm overnight at 4℃. The beads were then washed three 
times with the assay buffer plus 0.1% Tween-20, followed by LI-COR Western analysis 
to detect the ubiquitinated AHR using the anti-ubiquitin IgG. 
 For AHR-SUMO1 protein analysis, 0.5 mg of MCF-7, 1-2 mg of wild-type Hela, 
and 2 mg of p23KD HeLa cells were harvested, lysed, and immunoprecipitated as 
mentioned above. Western blot was subjected to anti-SUMO IgG for analysis.  
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2.2.10. Isotheral titration calorimetry (ITC). Calorimetric titration was carried out 
on a PEAQ-ITC (Malvern, Northhampton, MA). 1.2 L of 6His-AHR aa1-216 was 
denatured purified with 6M guanidine hydrochloride, refolded, and dialyzed into a final 
buffer of 25 mM HEPES, pH 7.4, 10% glycerol, 0.3M arginine, 4mM ATP. 300 µL of 
AHR (100 µM) was loaded into the sample cell. 6His- p23 WT (1 mM) was natively 
purified and concentrated in the same buffer and titrated into the ITC cell containing 
AHR. The initial injection of 0.4 µL was followed by 18 injections of p23 WT (2 µL) 
were injected into the cell at 25℃. Integration of the thermogram after the subtraction of 
blanks yielded a binding isotherm that fit best to a model on set of binding sites. The 
following blanks were performed: (1) 1 mM purified p23 WT titrated into buffer; (2) 
Buffer titrated into 100 µM AHR. The data were fit by a nonlinear simplex and 
Levenberg-Marquardt algorithm and yielded the Kd, ΔG, ΔH, and TΔS using the ITC data 
analysis module in MicroCal software.  
2.2.11. Statistical analysis. GraphPad Prism 7 software (La Jolla, CA) was utilized 
for statistical analysis. Two-tailed unpaired t-test determined the statistical significant 
difference with 95% confidence intervals with *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001, and ns, not significant (p > 0.05). In some cases, unpaired t-test using 
the Bonferroni-Dunn method was used to determine statistical significance (Fig. 3B and 
4B).  
 
49 
 
2.3. Results  
2.3.1. Stable knockdown of p23 in HeLa cells decreases the ahr message 
content and increases the AHR protein degradation. Our p23 knockdown (p23KD) 
stable HeLa cells has 55% and 50% of the ahr/AHR message and protein contents, 
respectively, when the p23 protein was reduced to 52% of the wild-type content (Fig. 3). 
This observation of the human AHR is consistent with our published results of the mouse 
AHR that down-regulation of p23 facilitates the AHR protein degradation [31].  
 
 
Fig. 3. Down-regulation of the p23 protein decreased the AHR protein levels in HeLa 
cells. Western results showing that AHR protein and message 
levels were reduced in p23 knockdown (p23KD) stable HeLa cells when normalized 
to the wild-type (WT) HeLa cells (arbitrarily set as 1). 
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2.3.2. Down-regulation of the Hsp90 and XAP2 proteins does not reduce the 
AHR protein levels. Five Hsp90 alpha-specific shRNA plasmids were able to down-
regulate Hsp90 alpha in HeLa cells to some extent (Fig. 4A, left panel). Less efficient 
down-regulation of Hsp90 was expected due to the importance of heat shock proteins for 
cell viability. Nonetheless, we observed that the Hsp90 protein levels could be reduced to 
as low as 55% with Hsp90-specific shRNA #1 when compared to the HeLa cells treated 
with the scramble shRNA. The Hsp90 down-regulated cells exhibited no significant 
change of the AHR protein levels (Fig. 4B). More effective down-regulation of XAP2 
was observed when compared to the Hsp90 down-regulation (Fig 4A, right panel and Fig. 
4B). Both XAP2-specific shRNAs (#2 and #3) effectively down-regulated the XAP2 
cellular content. XAP2-specific shRNA #2 down-regulated 84% of XAP2 expression 
while the AHR protein levels were unchanged. Collectively, down-regulation of XAP2 
and Hsp90 caused no reduction of the AHR protein levels, suggesting that p23 has a 
unique mechanism of modulating the AHR protein levels, which cannot be explained by 
merely alteration of the AHR cytoplasmic complex.  
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Fig. 4. Down-regulation of the Hsp90 and XAP2 proteins did not decrease the AHR 
protein levels in HeLa cells. AHR protein levels were determined by Western analysis in 
Hsp90- (left panel) and XAP2- (right panel) knockdown stable HeLa cells. Eight cell 
lines were examined: wild type (WT), negative control knockdown stable (NC), Hsp90 
knockdown (KD) #1-3, 5, 6, and XAP2 knockdown (KD) #3. The images in left panel 
were performed once whereas images in right panel were repeated with different samples 
twice with similar results (n=3). (B) Western analysis of AHR, Hsp90, and XAP2 
expression in wild-type HeLa cell (WT), scramble shRNA-treated stable HeLa cells 
(NC), Hsp90-knockdown stable HeLa cells using #1 shRNA (Hsp90KD), and XAP2-
knockdow stable HeLa cells using #2 shRNA (XAP2KD). Images on top are 
representative of the replicates and the graph was plotted below (n=6, means + SD). Each 
lane of A and B contained 40 µg of whole cell extract and was normalized by GAPDH. 
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2.3.3. Bacterially expressed GST-p23 promotes the formation of the AHR gel 
shift complex in vitro. In an effort to examine how p23 controls the AHR protein levels, 
we generated various GST fusions of p23 to study the p23: AHR and p23: Hsp90 
interactions. To ensure that GST-p23 is functional, we tested whether it can promote the 
formation of the AHR/ARNT/DRE complex in vitro since our previous data showed that 
the bacterially expressed histidine fusion of p23 (6His-p23) can effectively promote this 
formation [30]. Results from our gel shift assay showed that GST-p23 promoted the 
ligand-dependent formation of the full-length Pichia expressed AHR gel shift complex 
with 6His-p23 as the positive control for comparison (Fig. 5A, left panel). Next, we 
explored whether GST-p23 could promote the formation of the AHR gel shift complex 
caused by a truncated human AHR lacking the ligand binding domain (C∆553, aa1-295) 
fused to thioredoxin (TH553). Both p23 fusions also formed the ligand-independent 
TH553/ARNT/DRE gel shift complex, further validating that GST-p23 is functional (Fig. 
5A, right panel). These gel shift experiments were repeated so that the gel shift 
complexes could be confirmed and quantified by their band intensities (Fig. 5B). 
Formation of the AHR gel shift complex requires exogenous proteins [87] and thus either 
Pichia extract or p23 was required to form the gel shift complex.  
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Fig. 5. GST-p23 promoted the formation of the AHR gel shift complex in vitro. (A) Gel 
shift assay images showing that GST fusion of p23 (GST-p23) and histidine fusion of p23 
(6His-p23) promoted formation of the βNF-dependent AHR/ARNT/DRE complex 
formation (left panel, lanes 1-6). AHR and ARNT are full length human proteins 
expressed in Pichia. Both p23 fusions also promoted the formation of the ligand-
independent AHR/ARNT/DRE complex with TH553 as the thioredoxin fusion of the 
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human AHR aa1-295, a constitutively active AHR construct (right panel, lanes 7-15). 
Samples with 6His-p23 and Pichia extract were controls. Arrows indicate the two 
different AHR gel shift complexes. The experiment was repeated and the gel shift band 
intensity was quantified using a LI-COR CLx Odyssey imager with either 
AHR/ARNT/βNF/Pichia extract/DRE or TH553/ARNT/Pichia extract to be arbitrarily set 
as one. The graph was plotted in B (n=4, means + SD). 
 
 
 
2.3.4. Control of the cellular AHR protein levels by p23 does not require 
Hsp90 or the p23-mediated protein folding property. We examined the requirement of 
p23 control of the AHR protein levels. We suspected that this p23 effect on AHR might 
be mediated through its interaction with Hsp90. Therefore, p23 mutants were generated 
to address this hypothesis. Specifically, we generated five p23 point mutants as GST 
fusions – W106A, W109A, D108A, D111A, and D112A – where a tryptophan or 
aspartate residue which is potentially important for the p23: Hsp90 interaction was 
changed to an alanine. Results from our GST pulldown experiments revealed that all five 
mutants had less affinity to Hsp90 when compared to the wild-type p23 (Fig. 6A and B). 
Among them, D108A has the least affinity with Hsp90, which was 12% of the wild-type 
p23 and was statistically similar to the GST negative control (Fig. 6B and C). On the 
contrary, D112A has the highest affinity with Hsp90 among the five mutants, which was 
41% of the wild-type p23. Next, we selected D108A and D112A with the lowest and the 
highest Hsp90 affinity, respectively, to restore the AHR protein levels in the p23KD 
HeLa cells via transient transfection as GFP fusions. We observed that both D108A and 
D112A could restore the AHR protein (Fig. 7A and B) levels to a similar extent as the 
wild-type p23, suggesting that interaction with Hsp90 is not necessary for p23 to 
modulate the AHR levels.  
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Fig. 6. Hsp90 interacted with p23 and its mutants. (A) Western blot comparing Hsp90 co-
precipitation of GST-wild-type (GST-p23) to GST and GST-p23 mutants W106A, 
W109A, D108A, D111A and D112A. 100% input represents the total amount of the test 
protein added to the sample to start the GST pulldown experiment. Blank arrows within 
the images indicate the Hsp90 band that was co-precipitated by GST-p23 as the positive 
control. The image is representative of replicate data. (B) Quantitative analysis of Hsp90 
co-precipitation with p23 mutants normalized to GST-p23 which was arbitrarily set as 
one. The plot is quantified data showing the means with error bars (mean ± SD, n=4). 
Statistical significance was calculated when compared to the negative control GST. (C) 
Normalized co-precipitation of Hsp90 by GST-p23 and mutants when the GST value was 
subtracted from all conditions. This plot was generated using the average values in B. 
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Fig. 7. GST fusion of wild type p23 and p23 mutants restored the AHR protein levels in 
p23 knockdown (p23KD) stable HeLa cells. (A) Western results showing GFP-p23 wild 
type (WT), GFP-p23 D108A, GFP-p23 D112A, and GFP-p23 CΔ50 restored the AHR 
protein levels in p23KD HeLa cells. UT, untransfected p23KD cells; no plasmid, p23KD 
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cells had undergone transfection with no plasmid; GST, p23KD transfected with the GST 
control plasmid.  The image is representative of triplicate data. Each lane contained 40µg 
of protein. (B) Quantitative analysis of Western blot in A. Statistical significance was 
calculated compared to untransfected (UT) p23KD cells or p23KD cells transfected with 
the GST control plasmid. (D) Florescence microscopy using a Keyence microscope 
showing that GFP-p23 WT was nuclear whereas p23 mutants (D108A and D112A) were 
cytoplasmic and nuclear. 
 
 
 
Although GFP-p23 appeared to be nuclear, GFP-p23 D108A and GFP-p23 D112A were 
both cytoplasmic and nuclear (Fig. 7D), showing that subcellular localization of p23 
might not be important for the control of the AHR protein levels. In addition, a p23 
construct lacking the terminal 50 amino acids (C∆50) which are thought to be essential 
for protein folding could equally be effective in restoring the AHR protein levels (Fig. 7A 
and B), indicating that protein folding property of p23 is not required for controlling the 
AHR levels.   
2.3.5. p23 interacts with the N-terminal 216 amino acids of AHR and this 
interaction cannot be inhibited in the presence of ARNT. We generated various 
thioredoxin fusions of AHR, namely TH553 (aa1-295), TH217-549 (aa217-549), and 
TH515 (aa516-848), to address whether p23 would directly interact with AHR. These 
fusions were expressed in BL21 DE3 and then enriched using metal-affinity purification 
prior to the GST pulldown experiments.  
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We observed that only TH553 was co-precipitated with GST-p23, but not when 
GST was used as the bait (Fig. 8A), suggesting that p23 binds to the N-terminal 216 
amino acids of AHR. GST-p23 D108A, GST-p23 D112A, and GST-p23 C∆50 all 
interacted with TH553 but not GST (Fig. 8B), further validating that p23, more 
specifically the aa1-110 p23 region (C∆50), interacts with the N-terminal region of AHR. 
This aa1-110 p23 construct was sufficient to restore the AHR protein levels in the p23KD 
cells (Fig. 7B).  
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Fig. 8. p23 interacted with AHR at the N-terminal 216 amino acids of AHR. (A) GST-
p23 wild type (WT) (left panel) but not GST (right panel) co-precipitated AHR aa1-295 
(TH553) but not AHR aa217-549 (TH217-549) or aa516-848 (TH515). TH, thioredoxin. 
Arrows indicate the location of the expected band. (B) All transfected p23 mutants were 
able to interact with TH553 similar to GST-p23 WT. All images are representative of 
triplicate data that are plotted with means + SD (n=3). (C) The above Western images 
showing that addition of affinity purified Pichia ARNT (5µL) did not interfere with the 
interaction between affinity purified GST-p23 (0.35 µL) and TH553 (5 µL). All images 
are representative of triplicate data that are plotted below with error bars ± SD (n=3). 
 
 
 
Collectively, these results are consistent with the possibility that direct interaction 
between p23 and AHR is essential for p23 to control the AHR protein levels. Although 
this N-terminal AHR region overlaps with the region where AHR interacts with ARNT, 
five-fold increase of the Pichia ARNT used for gel shift assay did not seem to affect the 
interaction between GST-p23 and TH553 (Fig. 8C). Doubling the amount of Pichia 
ARNT (10 µL) still did not affect the p23: AHR interaction (data not shown). To further 
validate the direct interaction of p23 and AHR aa1-216, purified proteins were subjected 
to isothermal titration calorimetry (Fig. 9).  
C 
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Fig. 9. Validation of p23: AHR 1- 216 amino acids. (A) Thermogram of p23 WT (in 
syringe) with AHR aa1-216 (in cell). (B) Integrated heat profile of the calorimetric 
titration plot shown in A. The solid line represents the best nonlinear least-squares fit to a 
single binding site model. This experiment was repeated twice. (C). Thermogram of p23 
WT (in syringe) with buffer (in cell). (D). Thermogram of buffer (in syringe) with AHR 
aa1-216 (in cell). C and D were set as controls to calculate the free energy, enthalpy, 
entropy, and dissociation constant of A.  
 
 
 
 
 
C 
D 
62 
 
Specifically looking at the observed differential power of p23: AHR (Fig. 9A) and the 
control experiments, this indicated a binding interaction occurred when p23 was directly 
added to the cell containing the N-terminus 1-216 amino acids of AHR as the differential 
power is eight times larger than that of p23 titrated into buffer and 33 times larger than 
that of buffer titrated into AHR (Fig. 9C and D, respectively).  
 
2.3.6. Reduced p23 content causes ubiquitination of AHR without ligand 
treatment. We examined whether the increase of the AHR protein degradation in the 
p23KD HeLa cells is related to the ubiquitination of AHR. It is well established that upon 
ligand binding, AHR undergoes ubiquitination, which leads to degradation of the receptor 
via 26S proteasome. In HeLa cells, we could observe the formation of the ubiquitinated 
AHR only when cells were treated with 3-MC for 2 h in the presence of MG132, a 
proteasomal degradation inhibitor (Fig. 10). Without ligand treatment, the ubiquitinated 
AHR was detectable in the p23KD HeLa cells, but not in HeLa cells, suggesting that the 
unliganded AHR in the p23KD HeLa cells undergoes ubiquitination, leading to protein 
degradation. The modest ubiquitin signals observed in the DMSO-treated HeLa cells 
versus the p23KD cells (Fig. 10, lane 4 and 6) were likely nonspecific background signals 
independent of AHR since MG132 was not added for accumulation of the ubiquitinated 
proteins. The increased ubiquitination of AHR is not due to decreased SUMOylation of 
AHR as neither the WT HeLa (Fig. 11 lane 2) nor p23KD HeLa cells (Fig. 11 lane 4) 
expressed AHR-SUMO1 compared to the known AHR-SUMO expressing cell line, 
MCF-7 (Fig. 11 lane 1).  
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Fig. 10. Down-regulation of p23 increased ubiquitination of AHR in HeLa cells. Western 
data showing that ubiquitinated AHR (AHR-Ub) could be observed when wild-type 
HeLa (WT) cells were treated with 3-MC for 2 h in the presence of 10 µM MG132 (lane 
2) and also when the p23KD HeLa cells were treated with 10 µM MG132 without ligand 
treatment (lanes 3 and 7). Lanes 1-3 and 4-7 are images from two separate Western 
experiments. Anti-ubiquitin IgG was used to detect the signals. Experiment to detect the 
ubiquitinated AHR in HeLa cells (WT) treated with 3-MC and MG132 (lane 1-3) was 
repeated once with comparable results (n=2). Experiment to detect the ubiquitinated AHR 
in WT HeLa and the p23-knockdown stable HeLa cells (p23KD) + 10 µM MG132 (lanes 
4-7) was repeated twice and plotted below the representative images (n=3, means + SD).  
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Fig. 11. Increased ubiquitination of AHR is not due to decreased SUMOylation of AHR. 
Western data showing that basal sumoylated AHR (AHR-SUMO1) could be observed in 
untreated MCF-7 cells but not HeLa cells (WT). Experiment to detect AHR-SUMO1 in 
WT and p23KD HeLa cells were repeated thrice without SUMO detection using 1mg and 
2mg cell lysate. MCF-7 cells (0.5mg) were included once as a positive control. 
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Chapter 3: Troubleshooting and Optimization 
 
Throughout this research various steps and/or experiments were optimized or 
troubleshooted to ensure results were reproducible. This chapter will focus on the 
different approaches and steps that occurred during this process.  
3.1. GST-p23 mutant purification  
Solution NMR spectroscopy originally cited 8 amino acids essential for p23 to 
interact with Hsp90—W8, W86, W106, D108, W109, E110, D111, and D112 [88]. 
However, only 5 of the 8 point mutations could be natively purified. Specifically, GST-
p23 point mutants W8A, W86, and E110A could not be purified. Looking at the 
Coomassie stain of each step of purification for these mutants (Fig. 12A-B), we are able 
see that most of the protein is concentrated in the pellet for mutants W8A and W86A.  
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Fig. 12. Coomassie staining of each step of native purification for GST-p23 mutants 
W8A, W86A, and E110A. (A) Native purification of GST-p23 W8A yielded a large band 
in the pellet indicating the formation of inclusion bodies and little yield within the elution 
fractions (highlighted by red box). (B) Comparable results can be seen in the purification 
of mutant W86A but not mutation E110A. (C) Coomassie stain of elution fraction 1 from 
1.2 L bacterial culture of these mutants compared to 600 mL of GST-p23 D108A and 
GST-p23 WT natively purified.  
 
 
 
Since a very faint band can be seen in the elution fractions for the tryptophan 
mutants, purification was repeated several times and the elution fractions concentrated to 
scale up the recombinant protein. However, this still did not produce enough protein to 
use within the GST-pull down assay (Fig. 11C). Typically, a large band seen within the 
pellet fraction is indicative of the protein of interest forming inclusion bodies, or 
aggregates with itself, and purification in the presence of a denaturant will yield enriched 
purified samples. Unfortunately, refolding the p23 mutant protein would introduce more 
variables and convolute the pull down assay results. Consequently, these mutants were 
withdrawn from the experiment.  
The lack of a large band in either the load or pellet fractions for p23 mutant 
E110A indicated this mutant was unable to be overexpressed in E. coli. This could be due 
to a mutation upstream of the multiple cloning site such as in the lac operon (lacO) 
sequence, frameshift or stop codon introduction before p23 cDNA. While the T7 
promoter sequence did include the base pairs upstream of the multiple cloning site, the 
C 
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lac operator falls immediately after the T7 primer sequence. Due to the nature of primer 
annealing and sequencing, the quality of the first 100 base pairs sequenced is unreliable. 
Consequently, it was hard to confirm a mutation occurred prior to the p23 gene. Like 
W8A and W86A, p23 E110A was removed from the experiment in the interest of time.  
3.2. p23: Hsp90 troubleshooting  
During the GST-pull down assay, the following troubleshooting points were 
identified: 
1. PAGE gels should not be used if made > 2 weeks old 
2. Primary antibody should be spiked every 4-5 assays  
3. NP-40 concentration should remain consistent 
4. ATP activity diminished after several freeze/thaws 
If the SDS-PAGE gel was prepared more than 2 weeks prior to being used, the bands 
would appear very distorted on the nitrocellulose membrane. Thus, gels were made and 
used within a 1 week time frame. Likewise, since primary and secondary antibodies were 
reused, the prepared dilution volume decreased over time and lead to incomplete 
detection of bands. Therefore, after every 4-5 assays, the antibody dilution was refilled 
with blocking buffer to 10 or 15 mL for the primary or secondary antibody, respectively, 
and more antibody was added (spiked) in from stock solutions. Since NP-40 is a very 
viscous detergent, small volumes were hard to titrate and remain consistent over multiple 
samples. This problem was alleviated by ensuring the reaction volume was set to 1 mL 
and 0.01% was obtained from a 10% stock solution. Finally, ATP activity diminished 
after 2 freeze/thaws and lead to false-negative positive control. Since ATP and NP-40 
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were essential for the in-vitro detection of p23: Hsp90 interaction, ATP was made fresh 
prior to each assay to ensure the positive control could be detected.  
 Lastly, reagent concentration was also a problem during this experiment. 600 mL 
of bacterial Hsp90 could be purified to 1.5 mL enriched sample which was then 
concentrated and buffer exchanged to a final volume of 150 µL. Based on the number of 
GST-p23 mutants being tested, one purification prep would yield enough Hsp90 for 4 
separate assays if 5 µL was used per reaction. However, not all purifications yielded 
similar concentrations, i.e. E1 dilute (Fig. 13A), E2 also contain Hsp90 (Fig. 13B), and 
concentration less than 10 times. This is mainly due to different people assisting with 
purification process and different emphasis being put on different steps of purification 
(Fig. 13C). During the troubleshooting process, individual purification samples were used 
to quickly assess the aforementioned issues. However, once it was confirmed different 
preps had different Hsp90 yields, all enriched samples were concentrated together.  
 
 
Fig. 13. Hsp90 purifications with different yields. (A) Coomassie staining of purification 
steps of Hsp90. Enriched protein solely in elution 1 (E1) fraction. (B) Coomassie staining 
of purification steps of Hsp90. Enriched protein in all elution fractions (E1-E3). (C) 
Western analysis of elution fraction 1 at different volumes purified by three different 
people.  
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3.3. Transient transfection 
 After the p23 mutants with decreased binding affinity to Hsp90 were identified, 
the next step was to evaluate the effect on AHR protein expression after transient 
transfection into p23KD HeLa stable cells. Similar to the 2012 paper, I tried to evaluate 
this by transfecting the V5 plasmid (Invitrogen, Carlsbad, CA) containing the p23 mutant 
via electroporation. However, the V5 tag could not be detected via western analysis after 
transfection.  
3.3.1. Electroporation troubleshooting. Since over 80% of the p23KD HeLa 
cells died within 60 hours of transfection, it was assumed the electroporation conditions 
were too robust for the HeLa cells compared to the p23KD Hepa1c1c7 cells published by 
Nguyen, et. al. Consequently, the electroporation settings were altered until the 
confluency of the cells remained above 70% (Table 2). By optimizing the electroporation 
settings, I was able lyse and load 40 µg total protein for Western analysis. Yet the 
exogenous p23 was still undetected.   
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Table 2. Conditions performed to optimize electroporation for the detection of V5-p23 
transfected into p23KD HeLa stable cells. Original denotes the conditions performed in 
2012 for the transient transfection of V5-p23 into p23KD Hepa1c1c7 cells.  
 
 
3.3.2. Western blot troubleshooting. Consequently, the following conditions 
were also performed to ideally lead to the detection of V5-p23:  
 
Table 3. Western conditions performed to optimize the detection of V5-p23 transfected 
into p23KD HeLa stable cells.  
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The V5 epitope is only 1.5 kDa in size therefore it was hypothesized that the exogenous 
p23 and endogenous p23 were resolving together on the gel. To combat this potential 
issue, exogenous p23 was probed first with the V5 antibody on an SDS-tricine gel. An 
SDS-tricine gel allows for great separation of proteins smaller than 30kDa. This was also 
repeated with a more concentrated V5 antibody to no avail. We also questioned whether 
the amount of transfected p23 DNA was not enough to be detected by western and 
doubled the transfection DNA. We also theorized that the p23KD HeLa cell line was 
harder to transfect and tested p23 electroporation with HeLa WT and p23KD Hepa1c1c7 
cells. In addition to this, the total loaded protein was increased to the maximum amount a 
10-well comb could hold (Fig. 14). Yet, transfected p23 was still undetected. A small 
band was seen when 100 µg of the cell lysate was loaded but the band was atypical 
(staining of non-specific bands within the same lane increased) and not reproducible.  
 
 
Fig. 14. Western blot of p23KD Hepa1c1c7 cells transfected with 30 µg of V5-p23 WT 
via optimized electroporation settings. 60-100 µg of total lysed protein was loaded into 
gel and probed with 1:1000 dilution of V5 antibody. Red box indicates expected region 
for V5-p23.   
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To understand if the electroporation protocol contributed to the issue, a GFP plasmid was 
transfected and analyzed (Fig. 15). Since the GFP plasmid was detectable after 
electroporation via fluorescence microscopy and Western analysis, I deduced the 
electroporation protocol was not the issue. Consequently, we questioned the integrity of 
the V5-p23 plasmid.   
 
Fig. 15. Western blot of p23KD Hepa1c1c7 cells transfected with 30 µg of pGFP2-N2 via 
optimized electroporation settings. 60 and 80 µg of total lysed protein was loaded into gel 
and probed with 1:200 dilution of GFP antibody.   
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3.3.3. Mammalian plasmid troubleshooting. To address this issue, a TnT 
coupled reticulocyte lysate system (Promega, Madison, WI) was used to translate the 
purified DNA in vitro and analyze via Western. This assay also determined if the V5 
antibody could detect the V5 tag and if the SDS-Tricine gel could separate V5-p23 WT 
from endogenous p23 (Fig. 16).  The TnT system transcribed purified mammalian DNA 
via the T7 promoter region within the pcDNA6/HIS plasmid. Since the issue was not 
resolved with optimized electroporation or Western conditions, we re-sequenced the 
plasmid. Initially, the plasmid was sequenced using the T7 promoter site showing that the 
p23 and V5 sequence were unchanged. The second sequencing was completed using the 
BGH reverse priming site to sequence the CMV enhancer region. However, the CMV 
region lies towards the end of the BGH sequencing region. Consequently, the quality of 
the latter 300 base pairs is not optimal as seen in Figure 17.  
We decided to clone p23 WT, D108A, and D112A sequence into the pGFP 
plasmid used previously for troubleshooting (Fig. 18). This was also done because 
protein expression could be tracked throughout the transfection incubation period by 
fluorescence microscopy. The electroporation process required an extensive amount of 
cells and purified DNA, so we also questioned if the transfection could be scaled down 
using a transfection reagent (Fig. 19). This optimization allowed us to detect transfected 
p23 and its effect on AHR expression using 1/6th of the reagents. 
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Fig. 16. Western blots of V5-p23 WT and V5-p23 D108A translated and expressed in 
rabbit reticulocyte cells. (A) 1 and 5 µL samples analyzed with SDS-Tricine gel and 
probed with both V5 and p23 antibodies. (B) 1 and 5 µL samples analyzed with SDS-
PAGE gel and probed with both V5 and p23 antibodies. 
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Fig. 17. The reverse complement of the V5-p23 WT sequenced using the BGH reverse 
priming site aligned to the CMV promoter region nucleotides 236-852. Consensus 
mismatches are highlighted. Red indicates nucleotide insertion. Yellow indicates base 
pair mismatch and blue denotes base pair deletion.  
 
 Consensus ACATT-G-TT-TT--G--TA--GTTATTAA-A-T--AAT-AA-TT--GGGG----TC 114   
CMV promot ACATT-GATTATT--GACTA--GTTATTAATAGT--AATCAA-TTACGGGG----TC 45 
WT #2 BGH  ACATTTGTTTTTTTTGGATAAAGTTATTAAAATTTGAATTAAATTTTGGGGGTTTTC 114 
 
 Consensus -TT--TT-AT--AGCCC-T-T-A-GGAGTT--CCG--TTACA-AA--TT-C--GTAA 171 
CMV promot ATTAGTTCAT--AGCCCATAT-ATGGAGTT--CCGCGTTACATAAC-TTACG-GTAA 95 
WT #2 BGH  TTTTTTTAATTAAGCCCCTTTTAGGGAGTTTTCCGGTTTACAAAAAATTTCATGTAA 171 
 
 Consensus A-TGG-CCG-CCTGG-TG-CCG--CCCAA-GACCCCCGCCC--TGA--T-AA-TAA- 228 
CMV promot A-TGGCCCG-CCTGGCTGACCG--CCCAACGACCCCCGCCCATTGACGTCAA-TAAT 147 
WT #2 BGH  AATGGTCCGGCCTGGGTGGCCGGCCCCAAAGACCCCCGCCCTATGATTTAAAATAAA 228 
 
 Consensus GA-GT-T-TTCC-A-AGTAA-GCCAATAGG---TTT-CATTGA-GTCAATGGG--G- 285 
CMV promot GACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGA 204 
WT #2 BGH  GAAGTTTTTTCCAA-AGTAAAGCCAATAGGAGTTTTTCATTGA-GTCAATGGGGTGG 283 
 
 Consensus GTATTTACGGTAAA-TGCCCA--TGGCA-TACATCAAGTGT-TCATATGCCAAGTA- 342 
CMV promot GTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTAC 261 
WT #2 BGH  GTATTTACGGTAAATTGCCCAACTGGCA-TACATCAAGTGTTTCATATGCCAAGTAA 339 
 
 Consensus GCCCCCTATT-AC-T-AA-GACGGTAAAT-G-CCGCCTGGCATTA-GCCCAGTACAT 399 
CMV promot GCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACAT 318 
WT #2 BGH  GCCCCCTATTAACTTAAAGGACGGTAAATTGGCCGCCTGGCATTAAGCCCAGTACAT 396 
 
 Consensus GAC-TT--GG-ACTTTCCTACTTGGCA-TACAT-TACGTATTAGTCATCGCTATTAC 456 
CMV promot GACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTAC 375 
WT #2 BGH  GACTTTTGGGAACTTTCCTACTTGGCATTACATTTACGTATTAGTCATCGCTATTAC 453 
 
 Consensus CATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACG 513 
CMV promot CATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACG 432 
WT #2 BGH  CATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACG 510 
 
 Consensus GGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAA 570 
CMV promot GGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAA 489 
WT #2 BGH  GGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAAAA 567 
 
 Consensus TCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGG 627 
CMV promot TCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGG 546 
WT #2 BGH  TCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGGGCGG 624 
 
 Consensus TAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCTAACTAGAGAACC 684 
CMV promot TAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCTAACTAGAGAACC 603 
WT #2 BGH  TAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCTAACTAGAGAACC 681 
 
 Consensus CACTGCTTACTGGCTTATCGAAATTAATACGACTCACTATAGGGAGACCCAAGCTGG 741 
CMV promot CACTGCTTACTGGC------------------------------------------- 617 
WT #2 BGH  CACTGCTTACTGGCTTATCGAAATTAATACGACTCACTATAGGGAGACCCAAGCTGG 738 
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Fig. 18. Circular plasmid maps of mammalian plasmids used during transfection 
troubleshooting [89, 90].  
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Fig. 19. Western blot of HeLa WT cells transfected with GFP and GFP-p23 WT using 
EcoTransfect reagent in 6 well plate.   
 
3.4. p23: AHR optimization  
 To address whether p23 could directly interact with AHR, we utilized the GST-
pull down assay. Since this interaction has never been studied before, a positive control 
was not available. Consequently, many conditions were tested to ensure the assay was 
stringent and negative controls were consistent. To begin, TH515 (the most abundant 
purified protein) and thioredoxin (TH) were tested utilizing the Hsp90: p23 assay and 
wash buffer without ATP, sodium molybdate, NP-40 (Fig. 20).  
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Fig. 20. Western blot of GST-pull down assay comparing thioredoxin and TH515 co-
precipitation with GST-p23, GST, or GSH beads. Red boxes indicate reaction lanes.  
 
 
 
This experiment was not stringent enough as the negative controls (TH: GST, TH: GSH 
beads and GST: TH515) were seen under these conditions. The following schematic and 
table were followed to diminish these interactions (Fig. 21 and Table 4):  
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Fig. 21. GST-pull down assay optimization schematic. 
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Table 4. Assay conditions performed to optimize the GST-pull down assay for p23: AHR 
interaction study. 
 
 
 
 
To briefly explain, compounds known to decrease non-specific binding, such as DTT, β-
mercaptoethanol, and NP-40, were added to the wash buffer and/or assay buffer. The 
assay was performed probing only TH affinity to p23, GST, and the glutathione (GSH) 
magnetic beads. If these interactions were decreased or abolished, the condition was 
tested against TH515. Similarly, this was done to ensure the TH515 did not interact with 
GST or the magnetic beads (Fig. 22A-G). Outside of adding detergents and reducing 
agents, the input (total AHR protein added) and magnetic beads were decreased to 
minimize random adsorption of proteins onto the magnetic beads (Fig. 22H). Although 
12.5% input showed the most diminished negative control precipitation, the proteins were 
decreased to 20% input. This conservative approach was taken because TH515 was the 
most abundant truncated AHR construct. Consequently, we did not want to hinder 
potential reactions due to decreased protein content. By reducing the input to 20% of the 
original protein content, this also conserved a significant amount of protein and reduced 
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the time spent for purification. As seen in Figure 22, truncated AHR constructs TH216 
and TH553 were significantly less than purified thioredoxin tag and TH515 even after 
purification was scaled up 4-fold and 2-fold, respectively, and concentrated. Overall, 
condition 6 was the best protocol to evaluate p23: AHR interaction.  
 
 
 
A 
B 
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Fig. 22. Western blot results of the GST-pull down conditions tested to minimize TH co-
precipitation with GSH magnetic beads, GST, and GST-p23. (A) Condition 1: Tween-20 
concentration was increased from 10% to 20% and 10mM BME was added to the wash 
buffer compared to the original protocol. (B) Condition 2: 0.1% NP-40 and 10 mM BME 
were added to the assay buffer and the wash buffer. (C) Condition 2 was tested with 
thioredoxin tag and TH515. However, TH515: p23 was completely abolished as well as 
decreased p23: beads. (D) Condition 4: glutathione magnetic beads were decreased from 
20 µL to 10 and 5 µL and tested with the original protocol. (E) Condition 4 was tested 
with thioredoxin tag and TH515. (F) Condition 5: Addition of BSA, 10 mM BME, and 10 
mM DTT were added to assay buffer. (G) 0.225 M imidazole added to assay buffer to 
determine if minimize negative control co-precipitation better than 10 mM DTT. (H) 
Condition 6: Decreased starting protein input by 50%, 25%, and 12.5%. 
 
 
H 
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Fig. 23. Western blot analysis of purified and concentrated TH and TH-AHR samples. 
 
 
 
3.5. ITC troubleshooting  
To validate the p23: AHR aa1-216 binding, ITC was performed using purified 
proteins.  We did not want the thioredoxin tag to interfere or influence the p23 
interaction, so the designated AHR region was cloned into a pET-His6 plasmid and 
purified.  Consequently, the solubility of AHR was decreased and inclusion bodies 
formed in the pellet (Fig. 24A). To maintain the native structure of AHR, induction was 
performed at 10°C to decrease the rate of protein formation and thereby decrease the 
aggregation of protein. While this slightly increased the amount of protein present in the 
load, this did not significantly impact the AHR enrichment (elution 1) (Fig. 24B). To 
properly evaluate protein: protein interaction with the ITC, the least abundant protein 
must be > 20 µM in a final volume of 300 µL.  Since native purification could not yield 
such results, we utilized 6M guanidine hydrochloride to denature AHR and purify via 
column affinity chromatography (Fig. 24C).   Elution fractions 1-3 were enriched and 
combined to be refolded in the presence of arginine and ATP.  As seen in Figure 23C, 
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minimal protein was lost during limited dialysis. The denatured purification process was 
optimized to further enrich elution fraction 1 by collecting 300 µL of sample then the 
column was capped with the remaining elution buffer and incubated at room temperature 
for 30 minutes. This increased the AHR dissociation from the cobalt resin by increasing 
the length of time imidazole interacted with the resin (data not shown).  
Even though denatured purification increased the total AHR protein compared to 
native purification, purification of 600 mL of bacterial culture sample only produced 
enough protein (100 µM) for three ITC runs. Consequently, 1.2 L of bacteria was 
inoculated to increase the yield. The p23 interaction was evaluated at lower AHR 
concentrations (2 µM, 20 µM, and 50 µM) however the thermogram showed no 
saturation (Fig. 25). We believed this is because it is unlikely that 100% of AHR was 
refolded accurately. 
  
Fig. 24. Coomassie staining of 6His-AHR aa1-216 (A) native purification after 37°C 
IPTG induction (B) native purification after 10°C IPTG induction and (C) denatured 
purification with 6M guanidine hydrochloride after 37°C IPTG induction. 10 µL of each 
purification step was loaded.  
A 
B 
C 
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Fig. 25. Troubleshooting thermograms of p23: AHR aa1-216. Cell concentration for 
AHR is listed below each graph. Syringe concentration for p23 was 10 times the 
designated cell concentration.  
 
 
 
 
Another issue that arose during the ITC experiment was accurately determining 
the AHR protein concentrations. Since the MicroCal instrument utilized the 
concentrations to calculate the kinetic parameters, we did not want to rely on Coomassie 
staining with BSA to provide an estimate of protein concentration. To quickly and 
accurately determine the AHR protein concentration, we first tried to use the 
ThermoFisher Scientific Nanodrop Lite Spectrophotometer (Rockford, IL). However, an 
error message would continuously appear when the instrument was blanked with buffer 
(25mM HEPES, pH 7.4, 10% glycerol, 0.3 M arginine, and 4 mM ATP). Further 
investigation determined that the absorbance of the blank was measured at 365nm, 
whereas protein samples were measured at 280nm. Looking at the absorption spectrum of 
ATP, little to no light can be absorbed at 365nm (Fig. 26). Consequently, the buffer 
cannot contain ATP when blanking the spectrophotometer. However, since ATP has high 
absorption in the 260/280 region (same region protein absorbance is measured), the 
protein concentration would be erroneous. Therefore, the Nandrop could not be used to 
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determine the protein concentrations for this ITC study. Instead the bicinchoninic acid 
(BCA) assay was used.  This assay took approximately 40 minutes to obtain sample 
concentrations. Consequently, if any dilutions needed to be confirmed following an ITC 
run, an additional 40 minutes was added prior to the next run.   
 
Fig. 26. Absorbance spectrum of ATP [91]. 
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Chapter 4: Discussion 
 
We previously reported that both the message and protein levels of the mouse 
AHR are reduced by approximately 50% in a p23 knockdown stable Hepa1c1c7 cells 
[31]. This extent of the AHR down-regulation is functionally significant: both the ligand-
induced, DRE-driven EROD and reporter luciferase activities are significantly reduced in 
p23 knockdown Hepa1c1c7 cells when compared to the wild-type cells. In an effort to 
address the human relevance on this regard, we conducted experiments and proved that 
the down-regulation can be observed in human (HeLa) cells. The p23 co-chaperone 
appears to be important in maintaining the human AHR protein levels by modulating the 
AHR protein degradation. This p23 effect is not caused by unrelated cellular events 
during stable cell generation since this reduction of the message and protein levels of 
AHR can be reversed with exogenous wild-type p23, confirming that this AHR reduction 
in human cells is p23-specific. At present, we cannot rule out the involvement of pre-
translational control since the amount of ahr transcript is consistently reduced when p23 
is down-regulated. 
  It is conceivable that down-regulation of p23 might affect the formation or the 
structural dynamic of the AHR cytoplasmic complex, thereby leading to the fate of 
receptor degradation. This argument is supported by the observation that geldanamycin 
disrupts the p23: Hsp90 interaction and releases AHR from the complex for proteasomal 
degradation [92]. Moreover, reduction of the Hsp90 client proteins Erb-B2 and HIF-1α 
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by docosahexaenoic acid in an A549 xenograft model is thought to be mediated through 
disruption of the Hsp90: p23 interaction [93]. However, decreased levels of the other 
components of the AHR complex – namely Hsp90 and XAP2 – does not cause reduction 
of the AHR protein. Although it has been reported that down-regulation of XAP2 in 
Hepa1c1c7 cells reduced up to 30% of the protein levels of the mouse AHR (Ahb-1 allele) 
[94], XAP2 apparently has different roles in affecting the human AHR signaling when 
compared to the Ahb-1 receptor [94]. Our knockdown results with XAP2 are in line with 
the observation that down-regulation of XAP2 does not affect the Ahb-2 allele of AHR in 
C2C12 myoblasts [93]. Collectively, we believe that this p23 effect on AHR is not 
merely affecting the turnover of the cytoplasmic complex. However, we cannot rule out 
the possibility that the assembly of the AHR cytoplasmic complex is more sensitive to 
p23 than to Hsp90 and XAP2, since both complex disruption and p23 down-regulation 
cause increased in AHR ubiquitination. In addition, down-regulation of p23 might trigger 
degradation of the AHR protein by altering the ATP binding status of Hsp90, as in the 
case of geldanamycin treatment. However, 24% of the wild-type Hsp90 content could be 
sufficient to form the p23-bound AHR complex to stabilize AHR. It is important to note 
that geldanamycin causes 70-80% degradation of the AHR protein as early as two hours 
after treatment [84, 92]. This time course of pronounce degradation is very similar to the 
ligand-triggered degradation of AHR via 26S proteasome, but is rather different from the 
sustained reduction of the AHR levels mediated by p23.  
 Although most p23 function involves Hsp90, p23 does not require Hsp90 for 
modulation of the AHR protein degradation. Such conclusion is supported by the findings 
using p23 mutants which have noticeably less binding to Hsp90. We generated a number 
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of p23 point mutants at the region that is known to be important for Hsp90 binding. 
Among them, we chose the mutant D108A with the least Hsp90 binding (12%) and 
another mutant D112A which retained >3-fold more Hsp90 binding (41%) to study 
whether this interaction is important to affect the AHR protein levels. Although W106A 
has been reported by another laboratory to have negligible Hsp90 binding [96], we did 
not use this mutant since it exhibited somewhat significant binding (19%) when 
compared to our GST control. Both D108A and D112A mutants, however, were able to 
restore the AHR protein levels similar to the wild-type p23, showing that interaction with 
Hsp90 is not a prerequisite for p23 to affect AHR levels. This is not entirely surprising 
since other researchers reported that p23 stabilizes citrate synthase against the thermal-
mediated aggregation in an Hsp90-independent manner [97]. From the context of what 
we know about p23 and AHR, it is somewhat challenging to comprehend how p23 can 
affect AHR without Hsp90 since p23 forms the AHR complex by association with 
Hsp90. Thus far, there is no definitive data to prove that AHR binds p23 independent of 
Hsp90, realizing that Hsp90 is ubiquitous and is clearly abundant in the rabbit 
reticulocyte lysates that were used for co-immunoprecipitation studies to prove the p23: 
AHR interaction [25]. In an effort to better address whether p23 binds AHR directly, we 
generated bacterial reagents – AHR constructs and p23 – which had undergone metal-
affinity purification so that any bacterial homologs of heat shock proteins should be 
minimized. Our data proved that p23 can bind AHR directly, which unveils the 
possibility that binding of p23 to AHR protects AHR from degradation. This p23: AHR 
interaction requires the N-terminal 216 amino acids of AHR and the N-terminal 110 
amino acids of p23. One might speculate that since this N-terminal AHR region binds 
DNA and ARNT, there should be some competition between p23 and ARNT in binding 
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at that region. Surprisingly we failed to observe any competitive binding at this AHR 
region: formation of the AHR/ARNT/DRE gel shift complex is not suppressed by p23 
and the p23: AHR interaction is unaffected by ARNT, suggesting that the p23: AHR 
interaction is rather complex and should be further investigated.    
 Interestingly, AHR in the p23 knockdown HeLa cells appears to be ubiquitinated 
without ligand treatment, explaining in part why the AHR protein degradation is 
enhanced when the p23 content is reduced. Likewise, this increased ubiquitination is not 
due to decreased SUMOylation. Previously researchers determined AHR can undergo 
post‐translational modification by SUMOylation and this modification could be reversed 
by SENP1 [36]. Two SUMOylation sites were identified, one in the bHLH domain (K63) 
and the other in the TAD domain (K510) of AHR. Since this study demonstrated p23 
directly interacts with the bHLH domain, it was hypothesized that the absence of p23 
decreased AHR stability by decreasing SUMOylation at K63 and subsequently increased 
ubiquitination. However, immunoprecipitation results show that AHR-SUMO1 is not 
present in 4 times as much cell lysate of WT HeLa and p23KD HeLa cells compared to 
the positive control, MCF-7 cells. Therefore, SUMOylation may be a characteristic 
unique to breast cancer cells or another SUMO isoform may be present in HeLa cells. 
Thus far, there are 4 confirmed human SUMO isoforms: SUMO1, SUMO2, SUMO3, and 
SUMO4 [97]. SUMO-2/3 show a high degree of similarity to each other and are distinct 
from SUMO-1. SUMO-4 shows similarity to SUMO-2/3 but differs in having a proline 
instead of glutamine at position 90 [97]. To ascertain if one of these isoforms is present in 
HeLa cells, the immunoprecipitation assay can be repeated and western probed with 
specific antibodies for SUMO2/3 and SUMO4. However very little research has been 
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reported on SUMOylation of AHR, so it is unlikely this is the mechanism behind p23-
mediated AHR expression.  
It is well known that the consequence of AHR ubiquitination, followed by ligand 
activation, is degradation via the 26S proteasome since MG132 treatment can attenuate 
the reduction of the AHR protein [83]. Without ligand treatment, AHR has been reported 
to undergo ubiquitination which is mediated by C-terminal hsp70-interaction protein 
(CHIP) – a ubiquitin E3 ligase [99]. The endogenous significance of this CHIP-mediated 
AHR degradation, however, is unclear since CHIP did not alter the fate of the AHR 
protein upon TCDD or geldanamycin treatment when comparing transformed lung 
fibroblasts derived from CHIP knockout to wild-type mice [97]. Although CHIP may not 
be involved in the normal disposition of AHR, it is tempting to ponder whether this 
CHIP-mediated degradation of AHR may become important when the cellular p23 
content is reduced. Another interesting observation is that the tau protein can be 
ubiquitinated by CHIP and this ubiquitination can be reversed by up-regulation of Hsp70 
[100], implying that the folding status of tau, which is likely affected by the cellular 
abundance of Hsp70, may control the CHIP-mediated ubiquitination. However, the 
ubiquitinated tau protein appears to accumulate as insoluble aggregates rather than be 
efficiently degraded by the 26S proteasome [101]. This is strikingly similar to our 
observation of the AHR degradation when p23 is down-regulated: Although we could 
show 3MC-triggered degradation of AHR when p23 was down-regulated, the AHR 
protein levels could not be restored with MG132 treatment in p23 knockdown stable 
Hepa1c1c7 cells [31] and p23 knockdown HeLa cells via transient transfection (data not 
shown). Rather, the AHR degradation was more pronounced in the presence of MG132. 
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This observation indicated that proteasomal degradation per se cannot fully explain how 
the AHR protein is degraded when p23 is down-regulated. In the case of the tau protein, 
it has been postulated that the ubiquitinated tau aggregates can eventually be degraded 
via autophagy [102]. In addition, it has been reported that MG132 can induce autophagic 
degradation of the progerin protein in dermal fibroblasts derived from individuals with 
Hutchinson-Gilford progeria syndrome [103] and expression of LC3-II, which indicates 
autophagic induction, can be promoted in MG132-treated MCF-7 cells [104]. Autophagy 
could be a mechanism for p23-mediated AHR protein degradation which should be 
further explored.   
 As with any research, troubleshooting and optimization is paramount for the 
growth of the researcher and significant contribution to the scientific field.  For this 
research, the following areas were outlined to further discuss the troubleshooting and 
optimization process: p23 mutant purification, p23: Hsp90 interaction, transient 
transfection, p23: AHR optimization, and ITC troubleshooting. Significant amount of 
time was spent trying to scale up the enrichment yield of GST-p23 mutants W8A, W86A, 
and E110A. For the tryptophan mutations, the solubility of the overexpressed protein was 
significantly decreased due to the formation of inclusion bodies during induction.  
Looking at the crystal structure of human p23 (Fig. 27), the second structure is primarily 
β-sheets and turns, and the mutated tryptophans lie within the β-sheet strands [105]. 
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Fig. 27. Crystal structure of human p23 is comprised of β-pleated sheets and turn. 
 
 
 
It is possible that the amine group within the tryptophan participated in hydrogen bonding 
to stabilize the strands or another tryptophan structural motif, such as a tryptophan zipper 
that was important for stabilization or hydrophobic packing and was disrupted when a 
smaller hydrophobic amino acid was introduced. To circumnavigate this issue, IPTG 
induction could have been perform at 10°C or even denatured purification and refolding 
to increase the yield. To ascertain if this issue is due to the mutation, I would also 
consider circular dichroism on the natively purified sample and the wild-type sample to 
determine if a structural change had occurred, followed by crystallography to further 
understand this change.  
Since an inclusion body band was not seen in the pellet for GST-p23 E110A, we 
inferred the issue lies outside of the mutation. Even though the mutants were sequenced 
after site-directed mutagenesis, this was to ensure the p23 cDNA was only mutated at the 
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designated region. The sequenced region included the GST tag, His tag, and multiple 
cloning site. Since the T7 promoter anneals only 2 base pairs upstream of the lac operon 
sequence, it is hard to determine if this portion of the plasmid contains a mutation as the 
quality of the first 100 base pairs sequenced is low. Likewise, the T7 terminator sequence 
did not yield any answers as again quality of the final base pairs is low. I would design a 
new set of primers to sequence 100 base pairs outside of the lacO sequence to truly 
determine if the problem is due to another mutation. Similar to the tryptophan mutations, 
I would also perform induction at a lower temperature and consider purification using a 
denaturant to see if the elution fraction of GST-p23 E110A is increased.  
Similarly, the solution to transient transfection troubleshooting could be due to the 
sequence of the expression vector. I believe the V5 could not be detected due to a 
mutation within the CMV promoter region preventing the mammalian cell line from 
properly expressing the protein. In order to further analyze this, I would perform 
quantitative PCR to determine the transfected plasmid message level. If the level is 
minimal this would point to the CMV promoter whereas significant levels would indicate 
translation turnover or a problem with the analysis. Since extensive Western 
troubleshooting was completed, this is unlikely. I would also consider transfecting only 
the purified plasmid DNA into the cell line or another V5 fusion protein to determine if 
the problem lies within the pcDNA6/V5 plasmid. If this is true, I would repeat bacterial 
transformation of the company plasmid and generate new glycerol stock to utilize for 
future cloning. Regardless, optimization of the transfection by using the GFP expression 
plasmid and transfection reagent significantly reduced cell manipulation and reagents 
used to perform the necessary replicates.  
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As with any in vitro experiment and discovery of novel protein: protein 
interactions, optimization is essential to establish good controls. For the p23: AHR 
interactions, a positive control was not available. Consequently, the practicality of the 
assay relied on the negative controls. Identifying the optimal condition was a delicate 
process. The conditions could not be too harsh as any p23: AHR interaction would be 
abolished nor could the condition interfere with the p23: GSH magnetic beads or GST: 
GSH beads. This was seen in condition 3 when β-mercaptoethanol and Tween-20 
concentration was doubled. Ultimately, decreasing the GSH magnetic beads, adding BSA 
and DTT, and increasing the salt reduced the random adsorption of protein onto the beads 
and diminished the negative control co-precipitation.  
Native purification of the N-terminal domains of AHR is very difficult. Even with 
a thioredoxin tag to increase protein solubility, very little TH553 and TH216-549 could 
be natively purified. Ergo decreasing the starting protein input, significantly save time 
and reagent.  Once optimal conditions that abolished the thioredoxin and AHR 
precipitation with GST and magnetic beads were identified, p23 direct interaction with 
AHR was more credible. Similarly, negative controls were prudent for ITC investigation. 
Although the purification and refolding process is less than ideal for ITC interactions, the 
fact the thermogram profile significantly differs from that of the controls suggest the p23: 
AHR interaction is real.  
It is plausible the difficulty of native purification is a characteristic of the bHLH 
and LBD domains of AHR. To avert this problem, yeast expression using Pichia pastoris 
could be executed to ideally purify the native form of these constructs without refolding. 
Similarly, more induction optimization could be done at lower temperatures and/or lower 
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IPTG concentration to find the optimal condition for bacterial AHR expression. 
Subsequently, these purified proteins could be utilized in the aforementioned GST-pull 
down assay and ITC studies.  
While at the time troubleshooting and optimization felt never-ending and 
burdensome, it was vital for the research and my development. As a result, I have learned 
to critically assess technical errors, re-evaluate the research question, identify overlooked 
components, and establish good controls. By understanding how p23-mediated AHR 
expression is regulated, this will provide additional information towards the development 
of AHR-targeted drug therapies for oncology, autoimmune diseases, cardiovascular 
disease, and diabetes.   
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APPENDIX A. METHODOLOGY 
 
The aforementioned methodology is pertinent to the above chapters. However, 
this research also utilized basic techniques that will be described in detail here for 
reproducibility.  
A1. Primer design 
  Primers used during DNA cloning were specifically designed according to the 
gene of interest and expression vector. Primers were between 30 and 60 nucleotides in 
which half of the sequence aligned with the expression vector’s N-terminus sequence of 
the restriction enzyme used to linearize the plasmid and the other half aligned to the start 
codon and beginning 15-30 nucleotides within the open reading frame of the gene of 
interest. The reverse primer was the reverse complement of the C-terminus portion of the 
restriction enzyme cut and stop codon of the gene of interest.  
 
A2. Polymerase chain reaction (PCR) 
PCR is used during molecular cloning for DNA amplification. PCR consist of 
three major steps: melting, annealing, and extension, that are repeated for pre-determined 
set of cycles. The reaction contains the gene of interest, priers, dNTPs and DNA 
polymerase. In short, the gene of interest is used as a template for primers to anneal to 
and synthesize copies of the template utilizing the DNA polymerase and dNTPs to 
produce millions of copies for subsequent cloning. During the melting step, all 
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components of the reaction are heated to 95℃, the ideal temperature to denature/unwind 
double stranded DNA. Then, the temperature is lowered to 55-65℃ to allow the primers 
to anneal to the specific region of the template. Following this step, the temperature is 
ramped up to 68-72℃, depending on the type of DNA polymerase used, to extend the 
DNA copy. For experiment completed for this research, this protocol was used: 95℃ 
(2 min), [95℃ (30 sec), 60℃ (30 sec), 72℃ (1 min/kb DNA)] X 35, 72℃ (10 min), 4℃ 
(∞).  For each reaction, 1 ng of the DNA template, 1.3 μL of each primer (200 μM stock 
solution in water), 0.2 μL of Q5 High-Fidelity DNA polymerase (New England Biolabs, 
Ipswich, MA), 5 μL of Q5 5X reaction mix (New England Biolab, Ipswich, MA), 0.5 µL 
dNTP, and nanopure water to make the final volume to 25 μL. Afterwards, PCR products 
are analyzed in a 0.8-2% gel, dependent on size of amplified DNA, in 1X TBE buffer. 
The TBE buffer is made from a 10X TBE buffer stock:  108 g Tris base, 55 g boric acid, 
40 ml of 0.5 M EDTA (pH 8.0), qs with deionized water to 1000 ml.  
 
A3. DNA cloning  
 Once the PCR product is separated on the agarose gel, the DNA is excised from 
the gel under 365nm UV light. The excised gel is subjected to DNA extraction and 
purification using Zymoclean Gel DNA Recovery (Zymo Research, Irvine, CA). The 
2mg of purified plasmid to carry the PCR product is incubated with one enzyme. 
Restriction enzymes are chosen based on the multiple cloning site (MCS) of the plasmid 
and the frequency at which the enzyme cuts the plasmid. For our lab, we chose enzyme 
that cut the plasmid once within the MCS. The linearized plasmid is confirmed via 
agarose gel separation listed in Appendix A1. Like the PCR product, the linearized 
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plasmid is excised and subject the gel recovery. The two products, PCR product and 
linearized plasmid are mixed together in the presence of 2X Gibson Assembly Master 
Mix (New England Biolabs, Ipswich, MA) to a final volume of 20 μl and incubated at 
50℃ for 15 minutes. The total amount of fragments range between 0.02-0.5pmol with 2-
3-fold excess of PCR product. Picomole calculations were done with the following 
formula: pmols = (weight in ng) X 1,000 / (base pairs X 650 daltons). Immediately 
following the Gibson assembly, the cloned plasmid is diluted 1:3 with nanopore water; 1 
μl is incubated with 40 μl freshly thawed BL21 DE3 electrocompetent cells; subjected to 
electroporation in a 2 mm gap electroporation cuvette charge at 2500V for 5ms. The 
electroporation product is mixed with 1 mL pre-warmed LB medium and incubated at 
37℃ at 250 rpm for 1.5 hours. 200 and 400 μl of the electroporation bacteria is plated 
separately on a LB agar plate with appropriate antibiotics and incubated at 37℃ 
overnight. The next day, up to sixteen bacteria colonies are picked using sterile 
toothpicks and incubated in 3 mL LB medium with the appropriate antibiotics at 37℃ for 
15-18 h. Following miniprep plasmid purification, the purified plasmids are subjected to 
another restriction enzyme digest and analyzed in an agarose gel. For clone confirmation, 
a different restriction enzyme is selected that is known to cut the plasmid and gene of 
interest to yield two fragments. Positive colonies are submitted to Functional Biosciences 
(Madison, WI) for sequence confirmation and then grown at 37℃ at 250 rpm overnight 
for glycerol stock preparation, maxiprep DNA extraction, or IPTG-induced protein 
expression.  
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A4. DNA miniprep  
 This protocol was done during DNA cloning for > 5 samples. Following 
overnight inoculation, the toothpick is carefully extracted from the sample to streak a new 
plate, then 3 mL culture is centrifuged at 3,100 g for 10 minutes. The supernatant is 
aspirated away and 200 μl of Buffer I (50mM Tris-HCl, pH 8.0, 10mM EDTA) is used to 
resuspend the cells via quick vortex. Then, 200 μl Buffer II (200mM NaOH, 1% SDS) is 
added to obtain the cell lysate. 200 μl Buffer III (3M sodium acetate, pH 5.5) is added to 
neutralize the lysate. The mixture is then centrifuged at 3,100 g for 10 min and the 
supernatant is transferred to a 1.8 mL microcentrifuge tube. 500 μl of phenol: chloroform 
is added, vigorously shaken, and centrifuged at 16,000 g for 10 minutes. 360 μl of the 
supernatant is transferred to a new microcentrifuge tube containing 40 μl of 3M sodium 
acetate and 800 μl of 100% ethanol. The mixture is mixed and chilled at -20℃ for 10 
minutes, followed by centrifuge at 16,000 g for 20 minutes. The supernatant is aspirated 
and the pellet is air dried at room temperature for 30 minutes. The dried pellet is 
resuspended with 20 μl of nanopure water. This purification process yields bacterial DNA 
and RNA. During clone confirmation via restriction enzyme digest, RNase A is added to 
eliminate RNA interference.  
 
A5. Glycerol stock preparation 
 Positive clones confirmed by restriction enzyme digest and sequencing are frozen 
down for long-term use. This done by growing a 3 mL overnight bacterial culture with 
appropriate antibiotics from the plate streaked during the DNA miniprep. 700 μl of the 
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overnight culture is mixed with the 300 μl 50% glycerol (v/v) to make the glycerol stock 
and stored at -80℃.  
 
A6. Protein expression and purification 
The pQE80, pThioHis, and pET-His6, and pET-42a vectors all have a cis-lacI gene 
responsible lac repressor overexpression. Consequently, this will suppress downstream 
protein expression from the lac promoter without an inducer. Therefore, 1mM ITPG is 
added to the inoculated bacterial culture to induce T4 DNA polymerase expression and 
subsequently protein of interest expression. The pQE80 and pET-His6 vectors have a 
highly regulated 6His tag N-terminus of the MCS and express as a 6His fusion protein. 
The pThioHis and pET-42a vectors have a thioredoxin and glutathione-s-transferase tag 
N-Terminus of the MCS and express as a TH or GST fusion protein. All expression 
vectors can be purified by immobilized metal ion column affinity chromatography.  
 
A7. IPTG induction screening  
 After positive clones are confirmed, the following protocol is executed to 
evaluated protein expression level. 3 mL of LB medium is inoculated with 1 colony and 
50 μg/ml appropriate antibiotic (ampicillin or kanamycin) at 37℃ with shaking at 250 
rpm overnight. 0.5 mL of the overnight culture is then added to 2.5 mL of fresh LB 
medium containing the same concentration of antibiotic with or without 1mM IPTG. The 
induction samples without IPTG are considered the negative control. The samples are 
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incubated at 37℃ with shaking at 250 rpm for 4 hours. After induction, 0.5 mL aliquots 
of the samples are centrifuged at 3,100 g for 10 minutes and the pellet is washed twice 
with cold PBS. The pellet is resuspended with 40 μL of 1X treatment buffer (60 mM Tris, 
pH 6.8, 10% glycerol, 4% SDS, 0.02% bromophenol blue, 5% β-mercaptoethanol), and 
boiled for 5 minutes at 100℃ to denature the protein. 40 μL of the samples (IPTG treated 
and non-treated) are separated on a 10-15% SDS-PAGE gel for Coomassie blue staining.  
 
A8. Large scale protein expression and purification  
 Once IPTG induction is confirmed in the positive clone, 1 colony is inoculated in 
100 mL of LB medium with 50 μg/ml appropriate antibiotic at 37℃, 250 rpm, overnight. 
Then the overnight culture is mixed with 500 mL of fresh LB medium, 50 μg/ml 
appropriate antibiotic, 1 mM (final) IPTG and incubated at 37℃, 250 rpm for 5-6 hours. 
The entire bacterial culture is centrifuged in a 500 mL conical tube at 3,100g for 10 
minutes and the pellet is washed with 25-30 mL pre-chilled PBS. The washed pellet is 
stored in a 50 mL conical tube at -80℃ until lysis. The pellet is resuspended with 13 mL 
purification buffer (25 mM HEPES, pH 7.4, 10% glycerol, 0.3 M KCl). The cell 
suspension is transferred to a round-bottom conical tube and sonicated at setting 10 for 30 
seconds on ice with a 2 minute rest 5 times. The sonicated product is homogenized 30 
times up and down using a type-B dounce and subjected spun at 16,000g for 30 min at 
4℃. The supernatant is homogenized again and loaded onto a pre-equilibrated cobalt 
resin (1 mL) column (Econo-Column, Bio-Rad) at 4℃. The resin is equilibrated by 
washing the resin with 13 mL deionized water and 6 mL purification buffer, sequentially. 
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For native protein purification, all lysis and purification steps are done at 4℃. The load 
(supernatant from lysis process) can flow through the column via gravity. The flow-
through is poured back into the column up to 5 times. The resin is washed to remove any 
non-specific bound protein with 6 mL purification buffer (Wash I), 6 mL purification 
buffer containing10 mM imidazole (Wash II), and 5 mL purification buffer containing 
0.5 M imidazole (elution buffer). The elution buffer is loaded onto the column in 1.5 mL 
increments. After 0.5 mL of the elution buffer has flowed-through the column, the 
column is capped and allowed to incubate for 30 minutes. This will ensure all the resin is 
exposed to imidazole and the sample is enriched. Enriched samples are collected 1.5 mL 
aliquots and labelled E1-E3. 20 μL aliquot of each purification sample is taken (load, 
flow-through, wash I, wash II, E1, E2, E3) and mixed with 20 μL of 1X treatment buffer 
and boiled for 5 minutes. The samples are analyzed on SDS-PAGE gel for Coomassie 
blue staining or Western blot to determine protein yield and purity.  Elution samples are 
stored at -80℃ until further use.  
 
A9. Denature protein purification 
 During induction, some recombinant proteins form inclusion bodies in the 
insoluble pellet and are harder to purify via native purification. In this instance, 6M 
guanidine hydrochloride (GuHCl) denatured protein purification is used and the protein is 
refolded to its native form. This process is like the procedure listed in A-7 except the 
purification buffer contains 25mM HEPES, pH 7.4-8, 6M GuHCl, 0.3M NaCl, 10% 
glycerol) and all purification steps are completed at room temperature. After the 600 mL 
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bacterial culture is harvested, the pellet is resuspended in the GuHCl purification buffer 
and sonicated at setting “10” for 1 min on ice. The cell suspension incubates at room 
temperature for 1 hour. Then the lysate is subjected to 3 more 1 minute sonications at 
“10” with 2 minutes rest between each. The lysate is homogenized 30 times using the 
dounce and spun at 16,000 g for 30 minutes at 15℃. The supernatant is loaded into the 
pre-equilibrated cobalt resin (1 mL) column and purification proceeds at room 
temperature utilizing the GuHCl purification buffer for wash and elution steps. For 
analysis purposes, samples will have to undergo acetone precipitation since GuHCl is 
incompatible with SDS-PAGE gel.  
 
A10. Limited dialysis and buffer exchange 
 Limited dialysis is performed to refold the denatured protein elution (E1). 2-3 
inches of snakeskin dialysis tubing with MWCO 3,5000 (Thermo Scientific, Rockford, 
IL) is rinsed in 200 mL of deionized water for 5 minutes. The elution product is loaded 
into the tubing and incubated in 75 mL of dialysis buffer at 4℃ for 1-2 hours. The 
dialysis bag is then transferred to the new buffer and incubated until the desired 
concentration of arginine is reached. The following table outlines the buffers used for 
refolding AHR NΔ515 and AHR aa1-216:  
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Table 5: Limited dialysis buffers 
 AHR NΔ515 AHR aa1-216 
1 
25 mM HEPES, pH 7.4, 10% glycerol, 
4 M GuHCl 
25 mM HEPES, pH 7.4, 10% glycerol, 
4 M GuHCl 
2 
25 mM HEPES, pH 7.4, 10% glycerol, 
2 M GuHCl 
25 mM HEPES, pH 7.4, 10% glycerol, 
2 M GuHCl 
3 
25 mM HEPES, pH 7.4, 10% glycerol, 
1 M GuHCl, 1 M arginine 
25 mM HEPES, pH 7.4, 10% glycerol, 
1 M GuHCl, 1 M arginine 
4 
25 mM HEPES, pH 7.4, 10% glycerol, 
1 M arginine 
25 mM HEPES, pH 7.4, 10% glycerol, 
1 M arginine 
5 
25 mM HEPES, pH 7.4, 10% glycerol, 
0.5 M arginine 
25 mM HEPES, pH 7.4, 10% glycerol, 
0.5 M arginine, 4 mM ATP 
6 
25 mM HEPES, pH 7.4, 10% glycerol, 
0.2 M arginine 
25 mM HEPES, pH 7.4, 10% glycerol, 
0.3 M arginine, 4 mM ATP 
7 25 mM HEPES, pH 7.4, 10% glycerol  
 
 
 
Afterwards, the dialysis product is centrifuged at 16,000g for 5 minutes at 4℃ to separate 
the insoluble protein pellet. The supernatant is transferred to a new 1.5 mL 
microcentrifuge tube and store at -80℃ till further use. In the instance, the protein elution 
does not need to be refolded an Amicon centrifugal filter based on the protein size 
(Millipore Sigma, Burlington, Massachusetts) was used to concentration and/or complete 
a buffer exchange.  
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A11. Bicinchoninic acid protein assay 
 A bicinchoninic acid protein assay (BCA) is used to quantify protein 
concentrations. The protein concentration is determined by comparing the absorbance at 
540 nm of the sample to bovine serum albumin curve ranging from 0 to 100 μg. The BSA 
samples are prepared in same buffer- at 0, 0.05, 0.1, 0.2, 0.3, 0.5, 0.7, and 1 mg/mL- as 
the protein samples and a 1:10 dilution is prepared for each protein sample. Then, 10 μL 
of the BSA and protein samples is added to a well of a 96-well plate. BCA assay reagents 
A and B (Thermo Scientific, Rockford, IL) are added together at 98% and 2%, 
respectively, and 190 μL of the A/B mixture is added to the wells containing samples. 
The plate is then incubated at 37℃ for 30 minutes and the absorbance is measure with a 
microplate reader at wavelength 540 nm. The protein concentration is determined by 
comparing the absorbance to the BSA standard curve.  
 
A12. SDS-PAGE 
 Sodium dodecyl sulfate – polyacrylamide gel electrophoresis (SDS-PAGE) is 
used to separate denatured proteins by molecular weight. SDS is an anionic detergent 
known to linearize and negatively charge proteins so that the proteins will move in th 
presence of a current. The polyacrylamide gel is made in-house and acrylamide 
percentage is dependent on size of analyzed proteins. Higher percentage gels are made 
for smaller size proteins < 20 kDa and smaller percentage gels are ideal for > 100 kDa. 
The following table lists the recipe for 2 gels made in 1.5 mm Mini-PROTEAN glass 
plate (Bio-Rad): 
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Table 6. SDS-PAGE gel recipe 
Separating Gel (bottom) Stacking Gel (top) 
Acrylamide 
Percentage 
 10 %   12 %   15 %  
  
Water 8.2 ml 6.9 ml 4.8 ml Water  3.4 ml 
acrylamide/bis- 
acrylamide (30/0.8) 
6.7 ml 8.0 ml 10.1 ml 
acrylamide/bis- 
acrylamide 
(30/0.8) 
0.575 ml 
1.5 M Tris Buffer, pH 
8.8 
5 ml 5 ml 5 ml 
0.5 M Tris Buffer, 
pH 6.8 
1.25 ml 
10 % ammonium 
persulfate(AP) 
100 µL 100 µL 100 µL 
10 % ammonium 
persulfate(AP) 
50 µL 
TEMED 10 µL 10 µL 10 µL TEMED 5 µL 
 
 
 
In short, each glass plate is cleaned with ethanol prior to use. The plates are 
sandwiched together and placed into frame and gel stand. 0.07% agarose is dissolved in 
1:3 dilution of water and low tris buffer and 0.5 mL of the agarose solution is poured 
between the two plates and allowed to solidify for 10 minutes. This is done as an extra 
precaution to ensure the plates do not leak. The separating gel recipe is prepared in an 
Erlenmeyer flask according the acrylamide percentage. The mixture is poured on top of 
the solidified agarose with 1 inch of space remaining at the top. ~2 mL of water is slowly 
added on top of separating gel to even out the gel surface. After 30 minutes at room 
temperature, the separating gel will harden and a clear line between the water and 
solidified gel will be present. The water is decanted and the top portion of the plate is 
dried with filter paper. The stacking gel solution is prepared and poured on top of the 
separating gel. A 10-well or 15-well comb is inserted into the stacking gel and hardened 
at room temperature for 4 hours. The gel is stored at 4℃ in water until further use. Once 
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samples are prepared for analysis, the gel is set up in a Mini-PROTEAN tank (Bio-rad) 
with 200 mL 1X TGS running buffer in the inner compartment and 150 mL 1X TGS 
buffer in the outer compartment. The denatured samples are loaded into each well of the 
stacking gel with a protein ladder, 5 μL of M-XStable prestained protein ladder is added 
for Western blots (UBPBio, Aurora, CO) or 10 μL of LMW protein ladder (Bio-Rad) for 
Coomassie blue staining. The samples are run at constant 150 volts for 10-15 minutes or 
until the samples pass through the stacking gel, then 200 volts for 30-45 minutes using a 
Bio-Rad Power Pac.  
 
A13. Coomassie blue staining 
 After gel electrophoresis has completed, the tank is disassembled and the gel 
plates are separated using a Bio-Rad gel separator tool. The gel is stained in 10-30 mL of 
Coomassie staining buffer (0.5 g brilliant blue, 100 mL acetic acid, 250 mL isopropanol, 
qs with water to 1000 mL) for 30 minutes. Afterwards, the gel is rinsed twice with 
deionized water and destained with 10-30 mL destain buffer (50 mL acetic acid, 100 mL 
methanol, qs with water to 1000 mL) overnight at room temperature. The gel is scanned 
with our lab’s LI-COR CLx Odyssey system (Lincoln, NE).  
 
A14. Western blot 
 In the instance a more specific analysis is required, a Western blot is used to 
detect the protein(s) of interest with specific antibodies. To do this, the protein contained 
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within the SDS-PAGE gel after electrophoresis must be transferred to a 6 cm X 8 cm 
nitrocellulose membrane (LI-COR Biosciences). The membrane is first activated with 
wet transfer buffer (3.03 g tris, 14.4 g glycine, 200 mL methanol, qs to 1 L) for 10 
minutes. After the membrane is equilibrated the “sandwich” is assembled as follows:  
clear frame of transfer cassette  sponge 2 pieces of filter paper  membrane  
SDS-PAGE gel  2 pieces of filter paper  sponge black frame of transfer cassette  
The tank is then assembled with a magnetic stir bar, ice pack, and cassette 
ensuring the positive (clear side) and negative (black side) orient with the appropriate 
electrode. The remaining wet transfer buffer is added to the tank and transferring 
proceeded at constant 30 mA for 120 minutes. Afterwards the tank and cassette are 
disassembled and the membrane is blocked with blocking buffer. Primary and secondary 
antibody incubation occurs as described above and the membrane is scanned.  
 
A15. In vitro translation 
Recombinant V5 fusion proteins are translated using TnT coupled reticulocyte 
lysate system according to manufacturer’s protocol. 25 μl of TnT rabbit reticulocyte 
lysate, 2 μl of TnT reaction buffer, 1 μl of TnT amino acid mixture minus methionine (1 
mM), 1 μl of T3 or T7 RNA polymerase (depending on the type of promoter of the 
expression vector), 1 μl RNase ribonuclease inhibitor (40 u/μl), 2 μg of expression 
plasmid, 1 μl of methionine, and RNase-free water is added to make the final volume of 
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50 μl.  The reaction mix is incubated at 30℃ for 90 min and then kept on ice or -80℃ for 
long-term storage.  The protein amount is analyzed by Western blot. 
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APPENDIX B. LIST OF OLIGONUCLEOTIDE PRIMERS 
pET-His6 Hsp90 
 OL728: 5’- TGAAAACCTGTACTTCCAATCCAATATGCCTGAGGAAACCC 
AGACCCAA- 3’ 
 OL729: 5’- TTCGGATCCGTTATCCACTTCCAATTTAGTCTACTTCTTCCA 
TGCTGATG- 3’ 
 
pET-42a p23 W8A: 
OL730: 5’- CCTGCTTCTGCAAAGGCGTACGATCGAAGGGACG-3’ 
OL731: 5’- GTCCCTTCGATCGTACGCCTTTGCAGAAGCAGG-3’ 
 
pET-42a p23 W86A: 
OL732: 5’- GAATCTGGCCAGTCAGCGCCAAGGTTAACAAAAGG-3’ 
OL733: 5’- TTTTGTTAACCTTGGCGCTGACTGGCCAGATTCG-3’ 
 
pET-42a p23 W106A: 
OL734: 5’- GTCGACTTCAATAATGCGAAAGACTGGGAAGATGG-3’ 
OL735: 5’- ATCTTCCCAGTCTTTCGCATTATTGAAGTCGACG-3’ 
 
pET-42a p23 W109A: 
OL736: 5’- AATAATTGGAAAGACGCGGAAGATGATTCAGATGG-3’ 
OL737: 5’- ATCTGAATCATCTTCCGCGTCTTTCCAATTATTGG-3’ 
 
pET-42a p23 D108A: 
OL738: 5’- TTCAATAATTGGAAAGCCTGGGAAGATGATTCAGG-3’ 
OL739: 5’- TGAATCATCTTCCCAGGCTTTCCAATTATTGAAGG-3’ 
 
pET-42a p23 E110A: 
OL740: 5’- AATTGGAAAGACTGGGCAGATGATTCAGATGAAGG-3’ 
OL741: 5’- TTCATCTGAATCATCTGCCCAGTCTTTCCAATTGG-3’ 
 
pET-42a p23 E111A: 
OL742: 5’- TGGAAAGACTGGGAAGCTGATTCAGATGAAGACAGG-3’ 
OL743: 5’- GTCTTCATCTGAATCAGCTTCCCAGTCTTTCCAGG-3’ 
 
pET-42a p23 D112A: 
OL744: 5’- AAAGACTGGGAAGATGCTTCAGATGAAGACATGG-3’ 
OL745: 5’- CATGTCTTCATCTGAAGCATCTTCCCAGTCTTTGG-3’ 
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pcDNA6/His B p23 D108A/D112A: 
OL782: 5'- TGTGGTGGAATTCTGCAGATACAATGCAGCCTGCTTCTGCA 
AAGTGGT-3' 
OL783: 5'- CGGCCGCCACTGTGCTGGATCTCCAGATCTGGCATTTTTTCA 
TCA-3' 
 
pThio His A-AHR aa216-549 
OL796: 5’- GATCTTCGAATTCCGCGGCCGCAGGGAGAGGTGCTTCATA 
TGTCGTCTAA-3’ 
OL797: 5’- GATTACTGCAGGTCGACTCTAGAGGTTAATCAATGCCTAGG 
TTTTTCATTAT-3’ 
 
pGFP2-N2 p23 WT/D108A/D112A 
OL819: 5’- GAGAATTCTCACGCGTCTGCAGGATACAATGCAGCCTGCT 
TCTGCAAAGTGG-3’ 
OL820: 5’- CGGGCCCGCGGTACCGCAAGCTTGATACTCCAGATCTGGC 
ATTTTTTCATCATC-3’ 
 
pGFP2-N2 p23 aa1-110 (CΔ50) 
OL819: 5’- GAGAATTCTCACGCGTCTGCAGGATACAATGCAGCCTGCT 
TCTGCAAAGTGG-3’ 
OL842: 5'- CGGGCCCGCGGTACCGCAAGCTTGATATTCCCAGTCTTTCC 
AATTATTGAAGTC -3' 
 
pET-His6 AHR aa1-216 
OL845: 5'-TTCGGATCCGTTATCCACTTCCAATCTACATTAAAGGAGA 
GTTTTCTGGA-3’ 
OL669: 5’-TTCGGATCCGTTATCCACTTCCAATCTAGTCTGCTCTGGG 
TTTTGCCCTCAGGAGCG-3’ 
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APPENDIX C. GLYCEROL STOCK NUMBERS 
 
Glycerol Stock Number Construct Strain 
GS 54 A&B pQE80L-p23 JM109 
GS 134 pCDNA6/V5-HisB Top10 
GS 135 pCDNA6/V5-HisC Top10 
GS 168 pGFP2-N2 XL1-Blue 
GS 189a&b pET-42a-p23(FL) BL21(DE3) 
GS 190a&b pET-42a-p23(1-110) BL21(DE3) 
GS 196 pCDNA6/V5-HisA JM109 
GS 255 pET-42a p23 FL JM109 
GS 395 pET-His6 TEV LIC cloning vector (1B) DH5alpha 
GS 483 pGEM-Hsp90 (from Sino Biological), d-f BL21 DE3 
GS 489 a&b pET-His6 Hsp90 #6 BL21 DE3 
GS 491 pET-42a p23m1 BL21 DE3 
GS 492 pET-42a p23m2 BL21 DE3 
GS 493 pET-42a p23m3 BL21 DE3 
GS 494 pET-42a p23m4 BL21 DE3 
GS 495 pET-42a p23m5 BL21 DE3 
GS 496 pET-42a p23m7 BL21 DE3 
GS 497 pET-42a p23m8 BL21 DE3 
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GS 499 pET-His6 Hsp90 #3 BL21 DE3 
GS 500 pET-His6 Hsp90 #4 BL21 DE3 
GS 501 pET-His6 Hsp90 #5 BL21 DE3 
GS 502 pET-His6 Hsp90 #7 BL21 DE3 
GS 503 pET-His6 Hsp90 #8 BL21 DE3 
GS 504 pET-His6 Hsp90 #9 BL21 DE3 
GS 509 pET-42a p23m6 BL21 DE3 
GS 516 pET-His6 Hsp90 #7 BL21 DE3 
GS 568 pThioHisC-AhRND515 #2 BL21 DE3 
GS 573 pGFP2-N2 XL1-Blue 
GS 578 pcDNA6/V5-His B p23 D108A #1 BL21 DE3 
GS 579 pcDNA6/V5-His B p23 D108A #7 BL21 DE3 
GS 580 pcDNA6/V5-His B p23 D112A #3 BL21 DE3 
GS 581 pcDNA6/V5-His B p23 D112A #7 BL21 DE3 
GS 585 pcDNA6/V5-His A p23 WT #2 BL 21 DE3 
GS 586 pcDNA6/V5-His A p23 WT #3 BL 21 DE3 
GS 587 pcDNA6/V5-His A p23 WT #4 BL 21 DE3 
GS 588 Thio-His CD553 JM109 
GS 589 pThio His A BL21 DE3 
GS 590a pThio His A AHR NΔ515 #4 BL21 DE3 
GS 590b pThio His A AHR NΔ515 #4 BL21 DE3 
GS 591a pThio His A AHR NΔ515 #6 BL21 DE3 
GS 591b pThio His A AHR NΔ515 #6 BL21 DE3 
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GS 600 pThio His A AHR 216-549 #1 BL21 DE3 
GS 609 pGFP2-N2 p23 WT #5 BL21 DE3 
GS 610 pGFP2-N2 p23 WT #9 BL21 DE3 
GS 617 pET-42a (same as GS84) BL21 DE3 
GS 618 pGFP2-N2 p23 WT #5.1 BL 21 DE3 
GS 619 pGFP2-N2 p23 WT #5.2 BL 21 DE3 
GS 620 pGFP2-N2 p23 WT #9.1 BL 21 DE3 
GS 626a pGFP2-N2 p23 D108A #2 BL21 DE3 
GS 626b pGFP2-N2 p23 D108A #2 BL21 DE3 
GS 627a pGFP2-N2 p23 D112A #2 BL21 DE3 
GS 627b pGFP2-N2 p23 D112A #2 BL21 DE3 
GS 632 pCDNA6/V5-HisA Top10 
GS 633 pcDNA p23_1-110 JM109 
GS 642 pGFP2-N2 p23 1-110 #4 BL21 DE3 
GS 648a pGFP2-N2 p23 D112A #2 BL21 DE3 
GS 648b pGFP2-N2 p23 D112A #2 BL21 DE3 
GS 652 pET-HIS6 TEV LIC AHR aa1-216 #1 BL21-DE3 
GS 653 pET-HIS6 TEV LIC AHR aa1-216 #2 BL21-DE3 
GS 654 pET-HIS6 TEV LIC AHR aa1-216 #3 BL21-DE3 
 
